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ABSTRACT 
 The differentiation of CD4+ T cells to different effector lineages in response 
to pathogenic stimuli is the core of the adaptive immune system. One of the 
effector subsets recently discovered is T-helper 17 (Th17) and it plays a 
predominant role in autoimmune diseases and inflammatory disorders. Within a 
short span of time extensive literature has been available on this subset. This 
subset not only helped us to better understand basic adaptive responses but also 
unlocked a complete new area of T cell plasticity. Presently we are aware of 
several Th17 lineage determining factors such as cytokine environment 
(TGFβ+IL-6) and transcription factor ROR-γt. The role of cell surface receptors in 
Th17 differentiation is not known and has remained an understudied area of 
investigation. 
In my thesis, I aimed to study the role of Notch cell surface receptors in 
Th17 differentiation. Using in vitro Th17 differentiation assays of human naïve 
CD4+ T cells, I have shown that Notch signaling, particularly Notch1, plays a 
crucial role in Th17 polarization. I have demonstrated that expression of Notch1 
is increased in human in vitro differentiated Th17 cells. By using pharmacological 
Notch signaling inhibitors and specific knockdown of Notch1, I have shown that 
Notch1 is necessary for Th17 differentiation. Overexpression of Notch1 in naïve 
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CD4+ T cells followed by Th17 differentiation resulted in an increase in IL-17 
secretion, which further supported my data. Furthermore, IL-17 promoter assays 
and chromatin immuno-precipitation (ChIP) experiments revealed that IL-17 and 
ROR-γt are transcriptional targets of Notch1. 
I have also observed that in vitro differentiated Th17 cells are plastic, as 
during the polarization of T cells towards Th17, they also secrete Th1 associated 
cytokine IFNγ. This suggests that there is flexibility in IL-17 positive cells to 
become IFNγ positive, and/or Th17 and Th1 share an overlapping differentiation 
program. This concept of flexibility in Th17 differentiation is very intriguing. The 
presence of these IL-17+/IFNγ+ double producer cells both in vitro and in vivo 
under inflammatory conditions makes it an area of active investigation. In this 
study I have also shown that Notch signaling not only regulates Th17 subset 
differentiation, but also controls Th1 component of the Th17 differentiation 
process. By using pharmacological Notch inhibitors and specific Notch1 
knockdown in human in vitro Th17 differentiation assays, I have shown that 
Notch1 signaling regulates IL-17 and TNFα expression but not IL-5 secretion. 
Notch1 overexpression led to increase in IL-17 and TNFα but not IL-5 secretion 
in Th17 differentiated cells. Chromatin immuno-precipitations and human T-bet 
promoter assays support that T-bet and ROR-γt, but not GATA3 are direct 
targets of Notch1 under Th17 differentiating conditions. 
A role of Notch signaling in Th17 as well as Th17/Th1 co-differentiation is 
further validated in vivo. Experimental Autoimmune Encephalomyelitis (EAE) 
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model is used to detect the effects of Notch signaling inhibition on Th17 and Th1 
subsets (in collaboration with Dr Barbara Osborne, University of Massachusetts, 
Amherst). In this mouse model of human multiple sclerosis several publications 
suggest a role of both IL-17 and IFNγ in EAE pathogenesis. We observed that 
Notch signaling inhibition by oral Gamma Secretase Inhibitors (GSI) in the EAE 
model ameliorates the symptoms as well as delays the onset of disease. We also 
observed a decrease in IL-17 and IFNγ cytokine expression levels among 
restimulated splenocytes and mononuclear cells of the CNS in GSI fed EAE mice 
as compared to animals fed with control chow. 
My study demonstrates a role of Notch signaling in dictating Th17 
differentiation. Further it determines the role of Notch signaling in regulating 
Th17/Th1 double producer population also. Thus I propose use of Notch 
inhibitors (GSI) as a potential therapeutic strategy to treat Multiple Sclerosis due 
to its ability to regulate pathogenic cytokines such as IL-17 and IFNγ.
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CHAPTER I 
INTRODUCTION 
Activation of naïve CD4+ T cells and differentiation 
After completing their developmental process in thymus, naïve T cells 
enter the blood stream, and they circulate continuously from blood stream to 
lymphoid organ and back to the blood until they encounter antigen. While 
circulating between lymphoid organs and blood stream these naïve T cells make 
contact with several antigen presenting cells (APCs) in lymphoid tissue. These 
contacts allow naïve T cells to undergo positive selection for self MHC: nonself 
peptide recognition as well as to experience positive survival signals. Naïve T 
cells (1 in 104-106 is specific for particular antigen) that recognize their specific 
antigen by T cell receptor (TCR) cease to migrate, and then become activated to 
proliferate and differentiate into effector T cells. The most important professional 
APCs are highly specialized dendritic cells and macrophages. This recognition of 
antigen with respect class II MHC on APCs by the TCR of naïve T cells is called 
antigen specific “Signal 1”. Clonal proliferation of naïve T cells also requires 
second or costimulatory signals called “Signal 2” by the same APC (Kindt et al., 
2007).  
Naïve T cells express CD62l (L-Selectin) which facilitates their homing to 
lymphoid organs by interacting with CD34 and GlyCAM1 (Nicholson, 2002). 
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Another cell surface marker by which naïve T cells are commonly 
characterized by is CD45RA. The cytoplasmic tail of CD45 antigen has intrinsic 
phosphatase activity that removes phosphate from tyrosine kinase, specifically 
Lck, in T cells and helps in the activation of T cells (Zamoyska, 2007). There are 
various isoforms of CD45; CD45RA is located on naïve T cells and CD45RO is 
expressed on activated T cells and memory T cells (Tchilian and Beverley, 
2002). Naïve T cells are negative for activation markers CD25, CD44, CD69 as 
well as memory cell marker CD45RO (De Rosa and Roederer, 2001). 
 
Naïve T cells Activated effector T cells 
CD4+, CD45RA+, CD45RO-, CD62L+, 
CD25-, CD44-, CCR7+ 
CD4+, CD45RA-, CD45RO-, CD62L-, 
CD25+, CD44+, CCR7- 
 
After activation, naïve CD4+T helper cells begin to divide and give rise to 
effector cells. These effector cells are CD4+ and are commonly divided into T 
helper 1, T helper 2 and more recently identified T helper 17 based on distinct 
cytokine profile and immuno-regulatory functions. T helper 1 (Th1) cells secrete 
cytokines IFNγ and TNFα and are important for eliminating intracellular infections 
by viruses, bacteria and provide an effective anti-tumor protection.  T helper 2 
(Th2) cells secrete cytokines IL-4, IL-5, IL-10 and IL-13 and are important in the 
defense against parasitic infections (Kidd, 2003). Over the years Th1/Th2 
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paradigm of T helper cells differentiation, which was first introduced by Mosmann 
and Coffman in 1986, helped us to explain phenomenon of adaptive immunity 
(Mosmann et al., 1986). Recently, this paradigm has been expanded with the 
discovery of a third subset known as T helper 17 (Th17) (Harrington et al., 2005; 
Langrish et al., 2005; Park et al., 2005). These cells secrete IL-17, IL-17F, IL-21 
and IL-22. The primary function of this subset is the induction of inflammatory 
responses against extracellular bacterial and fungal infections. 
The Th1, Th2 and Th17 cells differentiation process is mutually 
antagonistic as well as self-reinforcing, that is: only one of the subsets is 
dominant in response to a given pathogen at any time. The important question 
that arises is what determines the differentiation pattern and immunological 
response against a particular pathogen?  
Although other subsets of CD4+ T cells are also been described in 
literature, for example T regulatory cells and other minor T helper subsets (see 
Table 1) including TGFβ producing Th3 (Chen et al., 1994), IL-10 producing TR1 
(Groux et al., 1997), IL-9 producing Th9 (Veldhoen et al., 2008b) and T follicular 
helper cells  (Nurieva et al., 2008), the primary focus of this thesis lies in 
differentiation of Th17 subset of T helper cells. 
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Th1 Th2 Th17 Th9 Tfh Treg
Signature
cytokine
IFNγ,TNF
α,
TNFβ
IL-4,5,
10,13
IL-17, IL-21,
IL-22
IL-9 IL-21
TGFβ,IL-
10
Transcripti
on
factor
Tbet, 
STAT4,Hl
x
STAT6,
GATA3,
c-maf
ROR-γt TGFβ, IL-4 FoxP3
Polarizing
cytokine
IL-12, 
IFNγ
IL-4 TGFβ/IL-6, 
TGFβ/IL-
6/IL-21/IL-
1β
IL-21 TGFβ,IL-
10,IL-2
Host 
defense
Intracellul-
ar
bacteria, 
Viruses.
Parasitic
Infections
Similar to 
Th1, mucosal 
immunity,
Extracellular
bacteria, 
fungi , 
parasites
Helminthes Suppressor
of  immune 
response
Pathogenic
role
Autoimmu
ne
Diseases.
Asthma
and 
allergies
Autoimmune 
Disease, 
psoriasis
Self
tolerance
T-Helper cells subsets
Table 1: Different T-helper subsets: Different subsets of T-helper cell subsets
are  shown.  This table emphasizes the differential cytokine environment,
transcription factor, signature cytokines secretes and role in normal as well
as pathogenic response of each subset.
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Th1/Th2 differentiation and its regulation. 
 
The concept of T helper 1 (Th1) and T helper 2 (Th2) type of cytokine 
production was emerged in the late 1980 by Mosmann and Coffman, originating 
from the observation that mouse CD4+ T cells clones could be classified into 
different subtypes of T helper population differing in cytokine secretion and 
immune-regulatory functions (Mosmann et al., 1986). This observation later 
revealed to be valid for human T cells as well (Romagnani, 1991).  
Naïve T cells undergo preactivation state called Th0 (Thprecursor) followed 
by differentiating towards either Th1 or Th2. This process is called polarization of 
T cells. Polarization of T helper cells into Th1, Th2 or recently discovered Th17 is 
a highly complex phenomenon which is regulated at multiple levels. It involves 
activation of cytokine genes specific for particular T helper cell subset and 
commitment of these polarized cells to effector phase. Simultaneously it also 
involves antagonizing expression of alternate cytokine genes. There are number 
of factors involved including the nature and affinity for  cognate antigen, type of 
TCR signaling, cytokine environment, transcription factors involved and 
epigenetic mechanisms that regulate the T cell differentiation process. These 
factors are discussed in detail below. 
 
Factors governing Th1/Th2 differentiation 
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Role of Antigen Presenting Cells (APC): The generation of immune 
response is antigen controlled by the interaction of antigen with APC. Evidences 
suggest that APCs including monocytes and macrophages themselves polarize 
into Th1 promoting DCs (DC1) or Th2 promoting DCs (DC2) depending on 
nature of processed antigen and then subsequently bias the polarization of T-
helper cells (Hertl, 2005). These DCs selectively express co-receptors, cytokines 
and other polarizing signals that promote differentiation of naïve T helper cells 
towards Th1 or Th2, for example DC1 (including macrophages) secrete IL-12 to 
promote Th1 polarization whereas DC2 (including mast cells and CD4+ NK like 
cells) secrete IL-4 to promote Th2 polarization (Liu, 2001; Rissoan et al., 1999). 
In response to antigen and associated adjuvants, recognition and binding via 
pathogen associated molecular patterns (PAMPs), APCs are driven to become 
DC1 and DC2 subtypes through toll like receptors (TLRs) expressed by APCs. 
Associated adjuvants such as polyI:C, LPS and CpG which act through TLR 3, 4 
and 9 respectively on DCs have a role in Th1 inducing signals (Dabbagh and 
Lewis, 2003). By contrast binding of PAM3Cys to TLR2 promotes Th2 inducing 
signals in DCs (Redecke et al., 2004). Preliminary data suggests that differential 
up-regulation of MAP kinase pathway explains the activation of DC to either the 
DC1 or the DC2 subtypes with p38 promoting DC1 and pERK promoting DC2 
(Agrawal et al., 2003). 
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T cell receptor (TCR) signaling and role of co-stimulatory molecules: 
Polarization of naïve T helper cells towards Th1 or Th2 subsets is 
regulated antigen regulation via TCR and by subsequent downstream 
intracellular signaling, for example activation of PKC, Ca2+ and signaling 
molecules such as NF-κB and NFAT (Noble et al., 2000). In addition of TCR 
signaling, costimulatory signals also regulate T helper cell differentiation, for 
example B7 and ICOS (Van Gool et al., 1996).  
It has been documented that early TCR signaling events differ between 
Th1 and Th2 subsets, for instance tyrosine phosphorylation profiles in Th2 cells 
are reduced as compared to Th1 cells. This may be due to difference in tyrosine 
phosphatase activity between Th1 and Th2 cells (Hannier et al., 2002). Among 
the costimulatory signals, the B7 family of protein plays an important role in the T 
cells differentiation process. It has been reported in in vitro differentiation assays 
that addition of anti B7.1 increases IL-4 production whereas neutralizing B7.2 
enhances production of IFNγ (Kuchroo et al., 1995). Similarly, another 
costimulatory molecule ICOS is particularly for Th2 responses as ICOS-/- T cells 
are specifically deficient in IL-4 production (Coyle et al., 2000; Nurieva, 2005; 
Watanabe et al., 2005). 
 
Cytokine environment:  
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The cytokine milieu generated by antigen presenting cells upon interaction 
with pathogen is the most influential factor regulating T helper cell differentiation. 
Th1 differentiation is initiated by secretion of IL-12 by macrophages and dendritic 
cells (Hsieh et al., 1993). A role of IFNγ is also appreciated in this process as in 
vitro neutralization of IFNγ inhibited Th1 differentiation (Farrar et al., 2002; 
Lighvani et al., 2001). It has been postulated that IL-12 promotes the release of 
IFNγ by DCs and natural killer cells, which in turn acts on DCs to produce more 
IL-12. Moreover, IFNγ released by APCs also acts as an inhibitor of Th2 cell 
proliferation. In the case of Th2, IL-4 produced by natural killer cells, eosinophils 
and mast cells regulate Th2 differentiation (Farrar et al., 2002; Lafaille, 1998). 
These cytokines upregulate and bind to their receptors expressed in naïve 
CD4+T cells, and then downstream signaling pathways involving various 
intracellular signaling cascades and transcription factors regulate specific T 
helper cell differentiation (Refer Fig.1). 
 
Transcription factors network:  
T helper differentiation is determined by the cytokine milieu and the 
resultant transcription factor network which is up-regulated specifically in either 
Th1 or Th2 subset differentiation. The crosstalk and interplay between these 
transcription factors culminates specific lineage. Differentiation of naïve CD4+ T-
helper cells towards the Th1 subset is initiated by Signal Transducers and 
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Activators of Transcription family of transcription factors (STAT) 1 and 4, which 
are activated in response of IFNγ and IL-12 respectively (Kaplan et al., 1996; 
Lighvani et al., 2001). STAT1 inturn regulates the T-bet promoter, a transcription 
factor important for Th1 differentiation (Afkarian et al., 2002). T-bet directly binds 
and transactivates the IFNγ promoter. Moreover it also induces the expression of 
H2.0-like homeobox (HLX) and RUNT related transcription factor 3, (RUNX 3) 
and binds as a complex with them to the IFNγ promoter (Djuretic et al., 2007; 
Mullen et al., 2002). T-bet indirectly regulates Th1 differentiation by binding to the 
GATA-3 promoter, negatively regulating its expression (Usui et al., 2006). It also 
complexes with RUNX3 and silences the IL-4 gene locus (Djuretic et al., 2007). 
T-bet binds to the IFNγ promoter even when DNA is methylated (repressive 
mark) (Chen et al., 2006a; Tong et al., 2005) and directly recruit histone 
demethylases (Jumonji domain containing protein demethylases) which removes 
the repressive Histone 3 Lysine 27 (H3K27) trimethylation mark (Miller et al., 
2008). This probably provides the mechanism by which overexpression of T-bet 
can reprogram differentiation of T cells towards Th1 in already committed Th2 
subets. Interestingly, STAT 4, T-bet and HLX form a multimolecular complex and 
regulate the IFNγ promoter, thereby reinforcing Th1 commitment (Refer Fig.1A) 
Similarly Th2 differentiation is governed by a network of transcription 
factors. Differentiation is initiated by activation of STAT 6, which is activated by 
IL-4 secreted by mast cells (Ansel et al., 2006). STAT 6 then binds and activates 
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GATA-3, which inturn activates transcription factor MAF and activates the IL-4 
promoter. GATA-3 along with MAF and STAT 6 regulates IL-4, IL-5 and IL-13 
promoters (Ansel et al., 2006) (Refer Fig.1B). 
 
Epigenetic mechanisms:  
During the differentiation process, T-helper cells undergo intrinsic cellular 
changes which are passed on to daughter cells. These intrinsic changes are very 
important for maintenance of self-reinforced differentiation status. These changes 
are mediated by epigenetic modifications which include chromatin remodeling by 
DNA methylation and histone modifications. A study by Bird et al has 
convincingly shown that epigenetic modifications can regulate T helper cells 
differentiation (Bird et al., 1998). They demonstrated that the use of either 
demethylating agent azadeoxycytidine or histone hyperacetylating agent 
trichostatin A can drive cells towards Th2 differentiation in presence of IL-4 even 
in STAT6 deficient T cells, despite the importance of this transcription factor for 
Th2 differentiation. Consistent with this data, the chromatin remodeling complex 
component Brahma Related Gene 1 (BRG1) regulated the IFNγ promoter in 
mouse Th1 cells and MLL (H3K4 methyltransferase) regulate GATA3, IL-4, IL-5 
and IL-13 expression (Yamashita et al., 2006; Zhang and Boothby, 2006).  
 
Identification of Th17 cells, novel subset of T helper cells  
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Novel discovered Th17 subset secretes IL-17 as the predominant 
cytokine, and it has immunoregulatory and effector functions different from the 
Th1 and Th2 subsets. Development of this subset requires a completely different 
cytokine milieu as compared to Th1 and Th2 subsets, and also requires crosstalk 
between different transcription factors to initiate differentiation.  
Initially Th1 cells were known to play predominant role in autoimmunity, 
but this concept was challenged when IFNγ and IFNγ receptor deficient mice 
were not protected from several autoimmune disorders, but rather developed 
aggravated form of disease (Krakowski and Owens, 1996; Zhang et al., 2003a). 
Mice lacking the expression of IL-12 p35 subunit, IL-12 receptor or IL-18 (crucial 
cytokines for Th1 differentiation) were also not protected against autoimmune 
disorders (Gran et al., 2002; Gutcher et al., 2006). This suggested the existence 
of a distinct lineage of T helper cells having a role in development of autoimmune 
disorders. 
The Th17 lineage was originally discovered in the year 2000 as a result of 
computational analysis which led to the identification of the p19 subunit. 
Interestingly this protein was later found to form a heterodimer with the p40 chain 
of IL-12, together was coined the novel cytokine IL-23 (Oppmann et al., 2000). 
This could explain the previous discrepancies as all earlier studies were based 
on antibody neutralization of the p40 subunit of IL-12 (subunit shared between IL-
12 and IL-23) and which could alleviate autoimmune disease. This strongly 
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suggested that IL-23, rather that IL-12, has a role in autoimmune disorders. To 
further elucidate the precise mechanism a systematic approach was used 
involving IL-23p19 and IL-12p35 knockout mice. As predicted it was found that 
IL-23p19-/- mice were incapable of developing autoimmune disease whereas IL-
12p35-/- mice were susceptible (Cua et al., 2003; Murphy et al., 2003). IL-23 is a 
regulator of IL-17 cytokine production as in IL-23p19-/- mice, the number of IL-17 
producing T cells were dramatically reduced (Langrish et al., 2005). On the basis 
of this finding a novel subset of T-helper cells “Th17” was proposed. After the 
discovery of the Th17 subset, it has become active area of research. Below is an 
overview of role of Th17 subset in health and diseases. 
 
Importance of Th17 subset in health and diseases 
Th17 cells as well as the cytokines released by them (IL-17A, IL-17F, IL-21, 
IL-22) play a role in a plethora of diseases, including inducing inflammatory 
diseases, autoimmune disorders and cancer (Dong, 2008). IL-17, signature 
cytokine of Th17 subset, is a member of a cytokine family group consisting of IL-
17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F since they all share common 
protein structure. Only IL-17A and IL-17F (around 50% amino acid identity) are 
expressed in subgroup of activated T cells during inflammation and induce 
release of chemokines (CXCL-1, CXCL-8) and cytokines (IL-6, IL-1β) from 
eosinophils which contributes to inflammation. Th17 cells exert their effect of 
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nonimmune cells by promoting release of matrix metalloproteinases (MMP 1,2,3 
and 9) which play a role in tissue remodeling and mucosal degradation. They 
induce secretion of several chemokines (CXCL-1,2,5,10,11,19,20) and cytokines 
(G-CSF, IL-6 and TNFα) which attract neutrophils and granulocytes, thus causing 
inflammation. Another important function of Th17 cells lies in regulating release 
of antimicrobial compounds, for example mucins (MUC5AC, MUC5B), β-
defensins and S100 which facilitate their role in immunity against anti-microbial 
immunity (as reviewed by (Dong, 2008).   
The protective role of this subset is against bacteria (Propionibacterium, 
Citrobacter rodentium, Klebsiella pneumoniae, Mycobacterium pneumonia), 
viruses (rotavirus, HIV), parasites (Toxoplasma gondii) and fungi (Candida 
albicans, Pnemocystis carinii) (Chung et al., 2003; Huang et al., 2004; Infante-
Duarte et al., 2000; Khader et al., 2007; Rudner et al., 2007). Besides playing as 
antimicrobial role in physiological adaptive immune responses, Th17 cells can 
become pathogenic in autoimmune diseases for example Multiple sclerosis 
(Matusevicius et al., 1999), Rheumatoid arthritis (Kirkham et al., 2006), 
Inflammatory Bowel disease (Duerr et al., 2006) , and psoriasis (Krueger et al., 
2007). 
 
Protective role of Th17 cells 
Host defense:  
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As mentioned before Th17 cells play a major role in antimicrobial 
immunity. A vast majority of publications suggest that a wide range of microbial 
disease can be prevented by the Th17 subset supporting a crucial role in 
adaptive immunity. Initially, the antimicrobial role of Th17 cells became evident in 
Lyme disease, caused by Borrelia burgdorferi. Authors used lysate from these 
bacteria and found that it increases Th17 differentiation of T cells in in vitro 
differentiation assays (Infante-Duarte et al., 2000).Subsequent studies further 
established the role of Th17 cytokines in immunity against microbial organisms. 
Given below is the role of IL-17 and other Th17 subset associated cytokines in 
host defense. 
IL-23 IL-23 p19 knockout mice are susceptible to K.pneumoniae 
infections (Happel et al., 2005). 
 
IL-17 IL-17 knockout mice are susceptible to K. pneumoniae 
infections. IL-17A play role in neutrophils recruitment as well 
as clearance of bacterias (Aujla et al., 2008). 
IL-17 increases bactericidal properties in macrophages 
against B. pertussis (Higgins et al., 2006). 
IL-17A and IL-17F increases neutrophils infiltration and 
clearance of M. pneumonia (Wu et al., 2007). 
IL-17R knockout mice are susceptible to Candida albicans 
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infections and injection of IL-17 protects against C.albicans 
infections in murine models (Huang et al., 2004). 
 
IL-22 Neutralization of IL-22 leads to severe of K. pneumoniae 
infection (Aujla et al., 2008). 
IL-22 promotes recovery of human bronchial epithelial cells 
after injury (Aujla et al., 2008). 
IL-22 induces secretion of antimicrobial peptides by 
epithelial cells (Liang et al., 2006). 
 
IL-21 IL-21 levels decreases in HIV infected patients, associating 
this cytokine with disease progression (Iannello et al., 2008). 
 
Role of Th17 in autoimmune diseases 
 Multiple Sclerosis (MS): MS is an autoimmune inflammatory disorder in which 
myelin sheaths around neuronal axons of central nervous system (CNS) (brain 
and spinal cord) are damaged, leading to demyelination and associated physical 
and cognitive disability. Various pro-inflammatory cytokines play a role in MS, for 
example IL-6, IFNγ, TNFα and IL-1β (Porrini and Reder, 1994; Rovaris et al., 
1996; Woodroofe and Cuzner, 1993). In 1999, first association between Th17 
cells and MS patients was presented by detecting high level of IL-17 mRNA 
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transcripts in blood and CNS of MS patients (Matusevicius et al., 1999). 
Furthermore patients with severe, opticospinal MS have higher levels of IL-17 in 
their cerebrospinal fluid than conventional MS patients and control subjects 
(Ishizu et al., 2005). Magnetic resonance studies have also suggested that there 
is a positive correlation between the extent of CNS inflammation, intracranial IL-
17 levels as well as breach of the blood brain barrier (Kebir et al., 2007). A recent 
study has shown that Th17 cells may directly interact with neuronal cells and can 
lead to their damage (Siffrin et al., 2010).  
Role of Th17 subset in MS is supported by using EAE, mouse model of 
MS. In this model, CNS proteins (Myelin basic protein, proteolipid peptide and 
myelin oligodendrocytes glycoprotein) are injected into mice which elicit auto-
reactive immune response, mimicking human MS symptoms. It has been shown 
that in IL-23p19 and IL-23 receptor deficient mice are protected from EA 
(Langrish et al., 2005; Zhang et al., 2003b). In addition IL-17 A knockdown 
attenuated the disease (Hofstetter et al., 2005).  
 
Rheumatoid arthritis (RA): RA systemic inflammatory autoimmune disorder that 
affects synovial joints. It also causes inflammation in organs like lungs, 
pericardium, pleura and sclera (Majithia and Geraci, 2007). A positive correlation 
between increased IL-17 in sera and severity and extent of inflammation in RA 
patients has been shown (Hwang and Kim, 2005 Chabaud, 1999 #15276; 
17 
 
 
 
Kirkham et al., 2006). The role of IL-17 in pathogenesis of RA was substantiated  
in vitro experiments where IL-17 can promote secretion of cytokines (IL-1β, IL-6 
and IL-23) and chemokines (CXCL-1,2,5,8) from chondrocytes, osteoblasts and 
fibroblasts (reviewed by (Lundy et al., 2007).  
Role of Th17 cells in RA is further emphasized by its mouse model, 
Collagen induced arthritis (CIA) in which collagen II is injected along complete 
Freund’s adjuvant. The symptoms of CIA mimic rheumatoid arthritis pathology 
including synovial hyperplasia, infiltration of T cells and damage of cartilage. It 
has been shown that IL-23p19 and IL-17 knockout mice were protected from 
collagen induced arthritis (CIA) (Murphy et al., 2003). Other cytokines produced 
by Th17 cells also play pathogenic role in CIA as blocking IL-21 attenuated CIA 
(Jungel et al., 2004; Young et al., 2007).   
 
Inflammatory bowel disease (IBD): IBD is a group of inflammatory disorder of the 
intestine including ulcerative colitis and Crohn’s disease. Correlation studies 
suggest association between IL-23R and IBD (Duerr et al., 2006). Promising 
results have been obtained in phase I and II clinical trials using STA 5326, a oral 
drug inhibiting both IL-12 and IL-23, in IBD patients (Billich, 2007; Burakoff et al., 
2006). IL-23 p19 knockout studies revealed protection of mice from T cell 
dependent colitis, also supporting a pathogenic role for Th17 cells (Elson et al., 
2007; Hue et al., 2006). It is suggested that Th17 cells, the inflammatory 
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cytokines that induce them (IL-1β, IL-6 and IL-23) and Th17 downstream 
mediators (chemokines, MMPs) all promote gut inflammation and are potential 
targets for treatment of IBD. 
 
Inflammatory skin disease and psoriasis:  Psoriasis is an inflammatory skin 
disorder marked by hyperkeratosis, epidermal hyperplasia and infiltration of 
several immune cells. The presence of Th17 associated cytokines, IL-17A, IL-
17F and IL-22 in the serum and lesional skin of psoriasis patients(Arican et al., 
2005) as well upregulation of transcript levels of RORC, IL-6, IL-1β and IL-23 in 
psoriatic skin (Wilson et al., 2007) suggest a role for the Th17 subset in the 
pathogenesis of this inflammatory disorder. Genetic Polymorphism studies also 
suggest a correlation between IL-23R variant and susceptibility to psoriasis 
(Capon et al., 2007). Presently a phase III clinical trial of human IL-12/IL-23 
monoclonal antibody (ustekinumab) is ongoing in psoriasis patients (Papp et al., 
2008). 
 
Role of Th17 in cancers 
Th17 cells and associated cytokines are implicated in several autoimmune 
and inflammatory diseases. The role of Th17 subset in cancer is very 
controversial and knowledge is currently limited. Th17 cells are present in tumors 
of both mouse and human origin (Kryczek et al., 2007). The important question 
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yet to be answered is whether these Th17 cells are tumor promoting or 
protective. Intradermal administration of IL-23 in carcinogen induced papillomas 
led to a decrease in intra-tumoral CD8+ T cells infiltration and enhanced tumor 
growth (Langowski et al., 2006) suggesting tumor promoting function of Th17 
subset. In contrast, intra-tumoral implantation of IL-23 transduced dendritic cells 
in glioma model resulted in an effective anti-tumor response involving infiltration 
by CD8+ T cells, CD4+ T cells and NK cells (Hu et al., 2006). Direct involvement 
deficient mice are highly susceptible to melanoma and their metastases to lungs 
(Martin-Orozco et al., 2009b). Administration of tumor specific Th17 cells led to 
marked reduction in tumor burden (Martin-Orozco et al., 2009b). In an another 
report using in vitro differentiation of melanoma antigen TRP specific CD4+ T 
cells towards the Th17 subset and adoptively transferred to mice carrying 
established melanoma tumors resulted in an effective anti-tumor response 
(Muranski et al., 2008). Interestingly Th17 cells mediated anti-tumor protection 
was dependent on IFNγ, as this effect was abrogated by IFNγ depleting 
antibodies (Muranski et al., 2008). Functional importance of Th17 cells has also 
been reported in ovarian cancer patients where the presence of IL-17 positive 
cells correlated with enhanced survival of patients (Horlock et al., 2009).  Further, 
in breast cancer patients a reduction in Th17 cells was shown and treatment with 
trastuzumab led to an increase in Th17 cells infiltration and increased overall 
survival of patients (Horlock et al., 2009).  
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An important question yet to be answered is that if IFNγ secreted by Th17 
cells is so important for anti-tumor response, what differentiates the role of Th17 
cells from Th1 differentiated cells (Muranski et al., 2008). Another crucial future 
area of investigation is defining the dynamics of Th17 cells and T regulatory cells 
within the tumor microenvironment. 
 
Regulation of Th17 differentiation 
Cytokine environment: In 2006, three independent laboratories indicated 
that IL-6 along with transforming growth factor (TGFβ) have a role in initiation of 
Th17 differentiation (Bettelli et al., 2006; Mangan et al., 2006). Later it was shown 
that IL-1β also has a role Th17 differentiation (Veldhoen et al., 2006). The 
indispensable role of TGFβ in Th17 differentiation is quite surprising as earlier 
reports showed TGFβ is an immunosuppressive cytokine which plays a role of T-
regulatory cells differentiation. Studies from Bettelli et al using GFP-FOXP3 
transgenic reporter mice has shown clearly that when present alone TGFβ leads 
to T-regulatory cells differentiation, but when present along with pro-inflammatory 
cytokines IL-6 and IL-1β, TGFβ leads to Th17 differentiation (Bettelli et al., 2006). 
Recently it has also been suggested that the concentration of TGFβ can play 
very important role in balance between T regulatory cells and Th17 cells, with low 
concentration of TGFβ supporting Th17 differentiation by increasing expression 
of the IL-23 receptor (Zhou et al., 2008).  
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Another cytokine which is important for Th17 differentiation is IL-6. It has 
been demonstrated both in vivo and in vitro that IL-6 induces IL-21 production in 
a STAT3 dependent manner, which in combination with TGFβ regulates IL-17 
production from naïve T helper cells (Zhou et al., 2007). 
IL-1β is another cytokine which is particularly important for Th17 
differentiation and expansion, as IL-1 receptor knockout mice display defective 
differentiation of Th17, but not Th1 and Th2 subsets (Sutton et al., 2006), along 
with a low incidence of EAE (Sutton et al., 2006). 
IL-23, composed of IL-12p40 and p19 subunits, plays an important role in 
Th17 differentiation as IL-23 knockout mice are resistant to EAE (Experimental 
autoimmune encephalomyelitis) (Cua et al., 2003), CIA (Collagen induced 
arthritis) (Murphy et al., 2003) and IBD (Inflammatory Bowel disease) (Yen et al., 
2006). But the precise role of IL-23 in Th17 differentiation is not known as IL-23 
alone cannot differentiate naïve T helper cells (Mangan et al., 2006). This may be 
due to the fact that naïve T helper cells do not express the IL-23 receptor, 
requiring IL-6 and IL-21 for its expression (Nurieva et al., 2007; Yang et al., 2007; 
Zhou et al., 2007). So the IL-23 is not required for initial differentiation of Th17 
cells but rather for maintenance of differentiation. 
Besides aforementioned positive regulators, IFNγ and IL-4 are very 
important negative regulators of Th17 differentiation. Neutralizing IFNγ and IL-4 
increases Th17 producing cells upon in vitro polarizations (Harrington et al., 
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2005) and IFNγ and IFNγ receptor deficient mice are highly susceptible to EAE, 
this is due to an increase in IL-17 producing cells (Harrington et al., 2005; 
Iwakura and Ishigame, 2006). 
Many studies, including ours, have shown the presence of IFNγ and IL-17 
double positive cells. This suggests that IFNγ may be important for Th17 cell 
pathogenicity or that both subsets share an overlapping differentiation program. 
The precise molecular mechanism of development of these cells or the role of 
double positive population is not at all clear. 
 
Transcription factor network: Complex interplay between transcription factors and 
cytokines is the most important Th17 lineage determining factor. Below is the 
overview of transcription factors playing role in Th17 differentiation: 
STATs: STAT1 and STAT6, transcription factors which define Th1 and Th2 
differentiation respectively seem to negatively regulate Th17 differentiation 
(Harrington et al., 2005). By contrast, STAT3 plays a supportive role in Th17 
differentiation. SOCS3 knockout mice (lacking the Suppressor of Cytokine 
Signaling) T cells have increased IL-17 production, which is due to hyperactive 
STAT3 signaling (Chen et al., 2006c). STAT3 binds directly to the IL-17 promoter 
(Chen et al., 2006c) as well as to the ROR (Retinoic acid related Orphan 
Receptor) family of transcription factor promoters (RORγt and RORα) (Ivanov et 
al., 2006; Yang et al., 2008b), key Th17 lineage determining transcription factors. 
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Retinoic acid related orphan receptor (RORs): RORα, β, γ, are each encoded by 
RORC gene using different promoters. RORα is important for development of the 
cerebellum and the lymph nodes, for lipid metabolism and for regulating immune 
responses. Its endogenous ligand is melatonin. The function of RORβ is not 
known but it is highly expressed in brain and retina. RORγ, particularly splice 
variant ROR-γt expressed in T cells defines Th17 differentiation (Jetten, 2004). 
During in vitro Th17 differentiation assays, ROR-γt expression is upregulated. 
Moreover retroviral transduction of naïve CD4+ T cells with ROR-γt vector leads 
to Th17 differentiation (Ivanov et al., 2006). Interestingly in ROR-γt knockout 
mice, the Th17 subset population is greatly reduced and protected from EAE 
(Ivanov et al., 2006). Another ROR family transcription factor, RORα, has been 
recently implicated in Th17 differentiation. RORα knockdown leads to impaired 
Th17 differentiation both in vivo and in vitro (Yang et al., 2008b). It has been 
shown that ROR-γt and RORα can bind to IL-17 gene locus and can 
cooperatively regulate IL-17 cytokine production (Akimzhanov et al., 2007; Yang 
et al., 2008b). Therefore interplay between STAT-3 and the ROR family of 
transcription factor regulate Th17 differentiation. (Refer Fig.2C) 
 
IRF-4 (Interferon regulatory factor 4): ROR-γt interacts with another transcription 
factor IRF-4. Overexpression of ROR-γt in IRF-4-/- T cells failed to fully 
differentiate into Th17. Also IRF-4-/- T helper cells have low IL-17 production and 
24 
 
 
 
exhibited higher FoxP3 levels (Brustle et al., 2007). Thus IRF-4 may be a 
determinant of Th17 and T regulatory cells balance (Yang et al., 2008a). 
 
FoxP3: The reciprocal relationship between T regulatory cells and Th17 
population is an active area of investigation. This follows as extensive immune 
responses have to be controlled by suppressive actions of T regulatory cells. 
TGFβ alone leads to differentiation towards T regulatory cells subset but together 
with proinflammatory cytokines (IL-6 and IL-1β) drives Th17 differentiation. A 
reciprocal relationship between Th17 and T regulatory subsets is regulated by a 
fine balance between FoxP3 and ROR-γt transcription factors. FoxP3 can directly 
bind to ROR-γt leading to inhibition of its transcriptional activity (Zhou et al., 
2008). FoxP3 can also bind to RORα through LXXLL sequence (Du et al., 2008), 
explaining the molecular basis of inter-relationship reciprocal relationship. When 
TGFβ is present in elevated concentrations it up regulates FoxP3 which in turn 
binds and inhibit both ROR-γt and RORα, thus inhibiting Th17 differentiation.  
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Cross talk between cytokines and transcription factor
In Th1,Th2 and Th17 differentiation.
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Figure 1: Schematic representation of cross-talk between cytokines and 
transcription  factors in differentiation of Th1, Th2 and Th17 subsets.
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AHR (Aryl hydrocarbon receptors): AHR are cell membrane receptors which are 
expressed in both T regulatory cells and Th17 cells. Surprisingly these receptors 
regulate Th17 and T regulatory cells in a ligand dependent manner. 2,3,7,8 
tetrachlorodibenzo p-dioxin (TCDD) regulate generation of T regulatory cells 
while another ligand of AHR, 6 formylindolo (3,2-b)-carbazole promoted Th17 
differentiation (Quintana et al., 2008; Veldhoen et al., 2008a).  
 
Nature and affinity of antigen: T-helper cell differentiation can also be regulated 
by the interaction of pathogen (antigen) with APCs. Factors such as antigen 
dose, toll like receptors (TLRs) activated and downstream TCR signal strength 
can regulate Th17 differentiation. Antigens including fungal wall component 
zymosan (a TLR2 activator on DCs), C-type lectins (pathogen associated 
molecular patterns recognition receptors on DCs) and NOD (Nucleotide binding 
oligomerization domain) like receptors upregulate IL-23 and skew T cells 
response towards the Th17 subset (Bird, 2010). TLR signaling, particularly via 
TLR2, plays a role in Th17 differentiation (for example, Pam3CysSerLys4 a TLR2 
agonist, skew T cells response specifically towards Th17) (Bird, 2010).  
A recent study published by Iezzi G has clearly shown the role of antigen 
dose, pathogen associated molecular patterns (PAMPs) and TCR stimulation in 
Th17 differentiation (Iezzi et al., 2009). Using in vitro differentiation of naïve CD4+ 
T cells specific to LCMV (Lymphocytic Chorimenigitis Virus) glycoprotein gp61-80 
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in presence of increasing concentrations of peptide, the authors have shown that 
at the highest dose of peptide antigen used (10µM), IL-17 producing cells were 
observed even in the absence of polarizing cytokines. Polarization was further 
increased using TGFβ and IL-6 or IFNγ and IL-4 neutralizing antibodies. In 
contrast low antigen dose (0.01-1µM) leads to Th2 differentiation and 
intermediate-high antigen dose to Th1 subset. The authors have also shown that 
high antigen dose and PAMPs synergistically regulate Th17 differentiation. They 
exposed splenic DCs to various TLRs agonists and pathogen related receptors 
(PRRs) and observed that TLR9 (CpG) and Dectin 1 ligands (zymosan and 
curdlan) upregulated Th17 differentiation which was further increased by high 
antigen dose (Iezzi et al., 2009). 
 
TCR and co-stimulatory molecules: The next step after antigen recognition in 
eliciting a specific Th17 immune response is downstream TCR signaling, which 
may be differentially upregulated in Th1, Th2 and Th17 differentiation. Several 
signaling events downstream of TCR engagement regulate Th17 differentiation: 
TCR proximal signaling: One of the important TCR proximal signaling that 
defines Th17 differentiation is through nonreceptor tyrosine kinases Tec (tyrosine 
kinase expressed in hepatocellular carcinoma). Knockdown of Tec family 
kinases, particularly Itk (IL-2 inducible T cell kinase), lead to defective IL-17A 
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production in in vitro differentiation assays. This defect was linked with 
impairment of Ca2+/NFAT pathway (Gomez-Rodriguez et al., 2009) 
Ca2+/NFAT: T helper cells differentiation can be regulated by Ca2+ signaling. Th1, 
Th2 and Th17 cells can be regulated by the duration, amplitude and pattern of 
Ca2+ signaling. Intracellular Ca2+ profiles of Th17 cells were different from Th1 
and Th2 cells. Th17 cells maintain sustained intermediate levels of Ca2+ in 
between Th1 and Th2 where Th1 display the highest intracellular Ca2+ levels. 
Interestingly authors have shown that these differences in Ca2+ levels may be 
associated with variation in phosphoPLCγ-1 where Th1  cells display the highest 
level of PLCγ-1 ( Th1>Th17>Th2) (Weber et al., 2008). 
 
NF-κB: Noncanonical NF-κB signaling (processing of NFκB precursor p100 to 
p52 and Rel B) plays a role in Th17 differentiation. CD4+ T cells from NIK-/- mice 
(lacking NF-κB inducing kinase, having distinct role in noncanonical NFκB 
signaling) were used to show that these cells fail to differentiate into Th17 cells, 
although differentiation towards to Th1 and Th2 proceeded normally. NIK-/- mice 
also failed to develop EAE. When comparing pSTAT3 (Tyr 705) expression 
levels between NIK-/- and NIK+/+ mice, authors found that NIK-/- mice lack up-
regulation of pSTAT3 by TCR and IL-6R signals (Jin et al., 2009). 
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miRNA: miRNA are short sequences (around 22nt in length) that regulate several 
biological processes including immune responses. miRNA species maintains 
secondary structure which is processed by the activity of RNAase III enzymes 
such as Dicer, Pasha and Drosha. Resulting short RNA duplexes then bind to the 
3’UTR of transcripts, inhibiting translation and/or hindering mRNA stability 
(Shivdasani, 2006). Initial studies of the role of miRNA in T cell differentiation 
showed that Dicer-/- T cells when differentiated to Th2, still showed IFNγ 
production suggesting miRNA plays a negative role in Th1 differentiation (Muljo 
et al., 2005). Furthermore miR155 was proposed to have role in T regulatory cell 
differentiation (Lu et al., 2009) and miR326 plays important role in Th17 
differentiation as well as pathogenesis of multiple sclerosis (Du et al., 2009). The 
miR326 regulates Th17 differentiation and EAE disease onset by inhibiting the 
translation initiation of Ets protein, which is a negative regulator of Th17 
differentiation. The miR326 expression levels correlate with IL-17 levels in MS 
patients. Furthermore a high level of miR326 transcripts were detected in 
peripheral blood of MS patients, thus suggesting a prognostic importance of 
miR326 detection for MS patients. 
 
Epigenetics: Since Th17 is a novel subset, regulation of IL-17A/IL-17F locus by 
epigenetic mechanism is currently an area of active investigation. The IL-17A/F 
locus is heavily histone 3 acetylated at eight different conserved noncoding 
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sequences (CNS) in Th17 differentiated mouse CD4+ T cells (Akimzhanov et al., 
2007). Corroborating this data CNS2 is regulated by both ROR-γt and RUNX-1 
(Zhang et al., 2008) transcription factors emphasizing a contribution of chromatin 
remodeling to Th cell differentiation. 
 
Plasticity of Th17/Th1 subset 
The concept of mutually exclusive and irreversible commitment towards 
Th1, Th2 and Th17 differentiation is mostly based on in vitro differentiation 
assays. Although these assays contribute to our understanding of basic 
mechanisms, in vivo conditions are much more complex. For example CD4+ T 
cells expressing IFNγ+/IL-17+ double positive population are commonly observed 
in vivo and in vitro in human T cells (Acosta-Rodriguez et al., 2007a; Acosta-
Rodriguez et al., 2007b; Wilson et al., 2007). Interestingly these double positive 
cells co-express markers of both Th1 and Th17 subtypes (for example 
CCR6/CXCR3 and Tbet/ROR-γt)(Acosta-Rodriguez et al., 2007b; Annunziato et 
al., 2007). T bet (transcription factor specific for Th1 differentiation) can be 
induced by IL-23 in Th17 cells and facilitate upregulation of IL-23R (Chen et al., 
2006b), supporting such plasticity. 
The presence of this population of mixed lineage cells sharing cytokines 
and transcription factors represents either flexibility of lineages to transform to 
another lineage, efficiently regulating immune process or merely representing 
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undecided population of cells during the differentiation process. This needs to be 
further evaluated.  A number of factors can potentially regulate plasticity including 
a heterogeneous cytokine environment in vivo, dual epigenetic modification, 
intermediate pathogen doses and T cell memory (Lee et al., 2009). Further 
discussion of Th17/Th1 cells is in Chapter 5. 
 
Notch structure and function:  
Another area of investigation which is currently understudied is role of cell 
membrane receptors as a potential participant in differential T helper cell 
differentiation. Among membrane bound proteins, Notch is an important 
candidate for having a role in T cell differentiation. Firstly Notch receptors are 
present on naïve CD4+ T cells (Palaga et al., 2003) and their ligands on antigen 
presenting cells (Ross and Kadesch, 2004; Yamaguchi et al., 2002). Secondly 
Notch has been shown to be activated after T cell receptor stimulus and 
interestingly co-localized with CD4+ at T cells-APC interface suggesting its role in 
modulating early T cells signaling events (Adler et al., 2003; Benson et al., 2005). 
Thirdly Notch is a cell fate determinant for T cells, driving a decision between T 
cells vs B cells (Pui et al., 1999), CD4 vs CD8(Robey et al., 1996) and αβ CD4 vs 
γδ CD4 T cells (Washburn et al., 1997). Therefore we can assume that Notch 
play important role in peripheral T cell differentiation also.  
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Notch structure 
The Notch is 300 kilodalton, class I heterodimer transmembrane 
receptors. In humans, there are four different paralogs of Notch receptors, 
Notch1-4 and five different types of Notch ligands Delta-like 1, 3 and 4 (DLL-
1,3,4)and Jagged1, and 2 (Jag1,2). Notch consists of extracellular domain (NEC), 
transmembrane domain (NTM) and intracellular domain (NIC). The NEC domain 
consists of variable glycosylated EGF-like repeats followed by cysteine rich Lin 
repeats which prevents ligand independent activation of Notch. The NTM consists 
of RAM domain (RBP-J associated molecule) which helps in interaction of Notch 
with effector transcription factor CSL; ankyrin repeats (ANK), which facilitates 
protein:protein interaction; transactivating domain (TAD), which is important for 
transcription and PEST (proline-glutamate-serine-threonine rich) domain which 
regulated Notch degradation (Radtke et al., 2010). 
 
Canonical Notch signaling: 
The Notch receptor is synthesized as a single large pre-protein in 
endoplasmic reticulum (ER). In Golgi, it gets O-glucosylated (by O-
glucosyltrasferase Rumi) followed by O-linked fucosylation (by O-
focosyltransferase, POFUT1). In Golgi, full length Notch receptor undergoes first 
cleavage by furin like proteases (S1 site) to generate non-covalent linked 
heterodimeric Notch. Before going to cell membrane, the extracellular domain 
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undergoes N-acetylglucosamination (by family of Fringes, Manic, Radical and 
Lunatic). The post-translational modifications by Fringes are very important for 
ligand binding affinity of Notch receptor with either Delta or Jagged. On the cell 
membrane it undergoes further cleavage by an ADAM (a disintegrin and 
metalloproteinase) protease at S2 site. The final processing of Notch by γ-
secretase complex at S3 site yields activated form of Notch1 (NIC) (Radtke et al., 
2010). NIC translocates to the nucleus and activates downstream transcription. 
γ-secretase is known to cleave vast number of  type 1 transmembrane protein 
substrates (Kopan and Ilagan, 2004). In fact, γ-secretase inhibitors (GSI) are 
under clinical trial to treat Alzheimer’s disease since it cleaves β amyloid protein 
(Borchelt et al., 1996). One of the other targets of GSI is Notch (De Strooper et 
al., 1999). There are number of pharmacological inhibitors of γ-secretase 
available including DAPT (GSI IX, Ly 374973,(3,5-Difluorophenylacetyl)-L-Alanyl-
PhenylGlycinebutyl Ester) (Dovey et al., 2001), Ly411,575 (DAPT derivative) 
(Searfoss et al., 2003), L685458 and L852647 (Merck) (Shearman et al., 2000). 
The NIC rapidly translocates to the nucleus where it interacts with the DNA-
binding repressor protein known as CSL (CBF-1/RBP-Jκ, mammals; Suppressor 
of Hairless, Drosophila; and Lag-1, C. elegans). In the absence of Notch 
signaling, CSL is bound to DNA in a complex with several repressor proteins 
consist of SMRT (silencing mediator of retinoic acid and thyroid hormone 
receptor), histone deacetylaces (HDACs), CIR1 (CBF1-interacting co-repressor) 
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and SHARP (SMRT/HDAC associated repressor protein) (Hsieh et al., 1999; 
Oswald et al., 2002; Shi et al., 2001).  NIC translocation to the nucleus and 
binding to CSL results in disruption of the repressor complex followed by 
recruitment of several co-activator proteins including SKIP (Ski-interacting 
protein), Mastermind like (MAML) and Histone acetyl transferases (HAT). This 
results in the initiation of transcription of genes located downstream of 
Notch/CSL complex (Miele, 2006; Osborne and Minter, 2007). 
 
Noncanonical Notch signaling:  
 Interestingly non-canonical Notch signaling is also documented in 
literature involving noncanonical Notch ligand (Delta/jagged) or CBF-1 
independent signaling. Various Notch ligands, besides conventional Delta and 
Jagged, are reported for example DNER (Delta/Notch like epidermal factor 
related receptor), Contactin, NOV (nephroblastoma overexpressed gene) and 
MAGP (myofibril associated glycoprotein) (Cui et al., 2004; Eiraku et al., 2005; 
Hu et al., 2003; Miyamoto et al., 2006; Sakamoto et al., 2002). The intriguing 
question is whether they play any role in immune cells? Another discussion is 
about their mechanism of action. It has been hypothesized that these ligands 
destabilize the heterodimeric domains of Notch and thus leads to the activation of 
downstream signaling. CSL independent signaling is originally described in 
Drosophila melanogaster, through E3 ligase deltex (Hori et al., 2004). But its role 
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in immune system is questionable as Deltex1 and 2 deficient mice showed no 
change in immune system development (Lehar and Bevan, 2006). Most studied 
and published Notch downstream signaling, besides canonical CSL pathway, is 
through NF-κB (Oakley et al., 2003; Oswald et al., 1998). A close examination of 
consensus binding sites of NF-κB and CSL reveals that both share overlapping 
motifs, suggest that may be there is competition between them to regulate gene 
expression (Lee et al., 2000; Vales and Friedl, 2002).  
 
Paradoxical role of Notch in Th1 and Th2 differentiation. 
Role of Notch in Th1 differentiation: Several reports suggest role of Notch 
signaling in Th1 differentiation. Pathogens such as virus (respiratory syncytial), 
bacteria (Acinetobacter lwofii and Lactococcus lactis) and TLR4 (CpG) 
upregulate Notch ligand DLL4 in dendritic cells through the Myd88 dependent 
pathway promote Th1 differentiation (Debarry et al., 2007; Napolitani et al., 2005; 
Rudd et al., 2007; Skokos and Nussenzweig, 2007). This is further supported by 
overexpressing Notch receptors (Notch 1 and Notch3) in CD4+ T and culturing in 
plate crosslinked DLL-Fc (DLL1 and DLL4) and observed upregulated  Th1 
differentiation (Maekawa et al., 2003; Minter et al., 2005). Evidences showing 
contribution of canonical (CSL) and noncanonical (NF-κB) signaling in Th1 
differentiation exist. Supporting a CSL dependent mechanism, Notch directly 
binds and activates Tbx21, the gene that encodes T-bet, in T cell hybridomas 
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(Minter et al., 2005). Another mechanism by which Notch promote Th1 
differentiation is through interaction with NF-κB. Notch is known to interact with 
p50 and p65 and regulates the IFNγ promoter (Shin et al., 2006). 
 
Role of Notch in Th2 differentiation: Role for Notch signaling in Th2 differentiation 
is also reported. In contrast to DLL-Notch signaling regulating Th1 differentiation 
it was observed that Jagged-Notch signaling regulates Th2 differentiation, 
suggesting that the Notch ligand involved may specify T cell fate (Amsen et al., 
2004). Antigens such as Schistosoma mansoni egg antigen (SEA), Vibrio cholera 
and prostaglandin E2 upregulate Jagged on dendritic cells and regulate Th2 
differentiation (Amsen et al., 2004; Kaisho et al., 2002; Krawczyk et al., 2008; 
Schnare et al., 2001). Genetic studies involving mouse CD4+ T cells deficient in 
CSL or dominant negative form of co-activator mastermind (MAML) resulted in 
abrogated Th2 responses in vitro and in vivo (Amsen et al., 2007; Tanigaki et al., 
2004; Tu et al., 2005). To rule out a Notch independent effect of CSL and MAML, 
Amsen et al used Notch1 and Notch2 double knockout mice and observed a 
similar defect on Th2 differentiation (Amsen et al., 2007; Barolo et al., 2000; 
McElhinny et al., 2008). Later GATA3 and IL-4 promoters were found to be direct 
targets of Notch, providing a molecular mechanism by which Notch can regulate 
Th2 differentiation (Amsen et al., 2004). The diagrammatic representation of the 
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paradoxical role of Notch signaling in both Th1 and Th2 differentiation is shown 
in fig.2. 
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Role of Notch signaling in differentiation 
of peripheral T cells
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Figure 2: Schematic representation of role of Notch signaling in T cell
differentiation: Notch1 is known to bind NF-κB subunits (p50 and p65) and
regulate IFNγ promoter. Additionally Notch binds to Tbx promoter and
regulate Th1 differentiation. On the other hand dominant negative
mastermind or conditional deletion of CSL led to defective Th2 phenype.
Role of Notch in regulation of Th17 differentiation is not known.
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Hypothesis and specific aims 
 
 Notch is an important regulator of peripheral T cell differentiation.  Role of 
Notch signaling in Th17 differentiation is not known. A recent publication 
suggested role of Notch ligand DLL4 in promoting expression of ROR-γt and 
expansion of mouse Th17 CD4+ T cells (Mukherjee et al., 2009). This led to my 
hypothesis that Notch signaling plays a defining role in Th17 differentiation, and 
inhibiting Notch signaling can be effective means of preventing Th17 mediated 
autoimmune diseases.  
 Role of Notch in Th1 and Th2 differentiation is known, but contradictory 
reports are present. The important question is whether these paradoxical results 
are due to different experimental method used, different Notch constructs or 
gamma secretase inhibitors used. In the current study, I used in vitro 
differentiation assays to study the role of Notch in T cell differentiation, 
particularly Th17. In addition, I also make efforts to compare and contrast role for 
Notch in Th1, Th2 and Th17 differentiation using same experimental system.   
 
Aim 1: To delineate the role of Notch signaling in Th17 polarization. 
My first aim is to determine whether Notch signaling regulates human 
Th17 differentiation. Using in vitro Th17 differentiation as my model system, I 
have shown that Notch signaling, particularly Notch1, regulates Th17 cytokine 
production including IL-17A, IL-17F and IL-22. The data presented in CHAPTER 
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2 demonstrate that in Th17 differentiated cells, there is increase in Notch1 
expression and downstream signaling. Blockage of Notch expression (by 
pharmacologic inhibitors or specific siRNA) results in reduced expression of Th17 
associated cytokines. Further overexpression of Notch1 in naïve CD4+ T cells 
resulted in increase in IL-17 production. 
 
Aim 2: To determine the molecular mechanism through which Notch regulates 
Th17 polarization.  
 I further investigated the regulation of human ROR-γt and IL-17 promoter 
by Notch1 to explain its mechanism of action. Specific knockdown of Notch1 and 
Chromatin immunoprecipitations (ChIP) are performed. Data shown in 
CHAPTER 3 has shown that ROR-γt is direct transcriptional target of Notch1. 
Moreover human IL-17 promoter luciferase assays and ChIP assays also 
suggest that IL-17 promoter is also regulated by Notch1.  
 
Aim 3: To determine whether Notch signaling inhibitors can prevent Th17 
mediated diseases in vivo. 
 EAE (Experimental Autoimmune Encephalomyelitis), mouse model of 
multiple sclerosis is used for this aim. The data presented in CHAPTER 4 using 
γ-secretase inhibitors demonstrate that Notch signaling regulates Th17 mediated 
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pathogenesis in EAE model and GSI reduced the disease symptoms and 
delayed the onset of disease as well. 
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CHAPTER II 
NOTCH FUNCTION AS A REGULATOR OF TH17 DIFFERENTIATION. 
Introduction 
Th17 cells as well as cytokines released by them (IL-17A, IL-17F, IL-21, 
IL-22) are very important for the immunity against bacterial and fungal infections. 
When the immune system is deregulated, for example autoimmune diseases, 
chronic disorders and cancers, the Th17 subset play a pathogenic role. Th17 
cells induce rapid accumulation of neutrophils at site of infection and promote 
secretion of inflammatory cytokines, chemokines and matrix metalloproteases 
(MMPs) (Korn et al., 2009). 
Various TLR signals, particularly TLR9, upregulate Notch ligand DLL4 
dependent IL-17 production in DO11.10 splenocytes (Mukherjee et al., 2009). 
Furthermore, adding DLL4 protein to mouse CD4+T cells upregulates the 
transcript levels of IL-17A, IL-17F, IL-22 and IL-23R suggesting a role of DLL4 in 
Th17 differentiation. Another study has utilized a pulmonary granuloma formation 
model in mice to emphasize role of DLL4 in Th17 regulation (Ito et al., 2009). 
They have shown that mycobacterial antigen, through TLR9, upregulate DLL4 in 
granuloma leading to Th17 response.  In addition, TLR9 knockout mice have an 
impaired Th17 response and displayed reduced DLL4 expression on dendritic 
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cells (Ito et al., 2009)Publications by the Elyaman and Jurynczyk groups have 
also provided evidence of role for Notch involvement in the Th17 mediated 
autoimmune disorder Multiple Sclerosis (Elyaman et al., 2007; Jurynczyk et al., 
2008b). They have shown that demyelinating lesions in MS as well its mouse 
model EAE express notch receptors and their ligands and observed active 
downstream Notch signaling within them. 
These observations led us to ask whether Notch signaling plays a role in 
human Th17 differentiation and which receptors this would involve. Under this 
aim we studied the involvement of Notch receptors in human Th17 differentiation. 
To follow human Th17 polarization we in vitro polarize naïve human CD4+ T cells 
towards Th17 subset. 
 
Results 
Differentiation of naïve human CD4+ T cells towards Th17 subset. 
 In order to study the role of Notch signaling in human Th17 differentiation, 
I used human in vitro Th17 polarization assay. I purified naïve CD4+ T cells from 
peripheral blood mononuclear cells by negative selection using MACS 
separation. The purity of naïve CD4+ T cell was assessed by staining with 
antibodies against CD4 and CD45RA. I obtained 93-96% pure population of 
naïve CD4+ T cells (Fig.3A). These cells were then stimulated and cultured with 
anti-CD3/CD28 beads under Th0 and Th17 polarizing conditions as mentioned in 
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materials and methods. I observed 3.5 fold increase (p≤0.01) in IL-17 levels 
starting from 24hrs when Th17 differentiated cells were compared with Th0 
differentiated cells (Fig.3B). I also compared human Th17 in vitro polarization 
using anti-CD3/CD28 beads vs coated plates and observed comparable (6-8 
fold) increase (p≤0.01) in IL-17 levels (Fig.4). Th17 differentiation was confirmed 
by intracellular staining of IL-17. I observed that intracellular IL-17 increased from 
1.25% to 11% when compared between Th0 and Th17 differentiated cells at 
72hrs (Fig.5). Interestingly, I also observed increase in IL-17+/IFNγ+ double 
positive cells (0.8 to 4%) in Th17 differentiated subset. When comparing ROR-γt 
transcript levels in Th17 differentiated cells with Th0 by real time PCR, I 
observed significant increase (4.5 fold; p≤0.01) in transcript levels starting from 
24hrs after differentiation (Fig.6). Levels of other Th17 subset associated 
cytokines were also measured in in vitro Th17 differentiated cells by ELISA. I 
observed 2 fold increase in IL-17F levels (p≤0.5) and 3 fold increase in IL-22 
levels (p≤0.01) in Th17 differentiated cells as compared to Th0 cells (Fig.7). Thus 
in vitro differentiated Th17 cells produce IL-17, IL-17F and IL-22 and have 
elevated ROR-γt transcript levels.  
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Figure 3: In vitro Th17 polarization of human naïve CD4+ T cells: Naïve 
CD4+ T cells were isolated from PBMC of healthy donors and were 
stimulated with anti-CD3/CD28 coated magnetic beads in Th0 (no 
cytokines) and Th17 (with skewing cytokines cocktail as mentioned in 
materials and method) conditions. A) Naïve T cells purity was checked by 
staining with CD4PE and CD45RAFITC.B) Supernatants were collected at 
indicated time points and analyzed for IL-17by ELISA. Data shown here 
represents one of at least three independent experiments performed in 
triplicates. *p≤.05, **p≤.01, ***p≤ .001.
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Figure 4: Comparing anti CD3/CD28 coated vs beads in in vitro Th17
polarization of human naïve CD4+ T cells: Naïve CD4+ T cells were
isolated from PBMC of healthy donors and were stimulated with anti-
CD3/CD28 coated magnetic beads or plate coated anti-CD3/CD28 and
differentiated towards Th0 and Th17 conditions. Supernatants were
collected after 72hrs and analyzed for IL-17by ELISA. Data shown here
represent the mean± SD for two independent experiments performed in
triplicates. **p≤.01.
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Figure 5: Intracellular IL-17 levels in human in vitro Th17 differentiated
cells. After 72hrs of in vitro Th17 differentiation, cells were stimulated with
PMA/Ionomycin for 4hrs and monensin for another 2 hrs. Cells were then
fixed and permeabilized as mentioned in materials and methods, followed
by staining with with anti-humanIL-17PE, anti-human IFNγ-APC and anti-
humanIL-4FITC and analyzed by flowcytometry.
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Figure 6: ROR-γt transcripts increases in human in vitro Th17 
differentiated cells as compared to Th0. Total RNA was isolated from invitro
differentiated Th17 cells at indicated time points, cDNA was synthesized and 
ROR-γt transcript levels were measured by quantitative real time PCR. Data 
represented were normalized against 18S RNA. Shown is mean SD of three 
independent experiments performed in triplicates.
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Figure 7: Upregulation of IL-17F and IL-22 in human in vitro Th17 as
compared to Th0 differentiated cells. Naïve CD4+ T cells were stimulated
with anti-CD3/CD28 coated magnetic beads and skewed towards Th0 and
Th17 subset. Supernatants were collected at indicated time points and
ELISA of IL-17F (A) and IL-22 (B) was performed. Data shown represent
mean SD experiments performed in triplicates. *p≤.05, **p≤.01.
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Upregulation of Notch1 in human in vitro Th17 differentiation assays. 
Expression level of Notch isoforms upon in vitro Th17 differentiation was 
assessed to study the role of Notch signaling in Th17 differentiation.  Whole cell 
lysates were prepared at several time points (24-72hrs) of Th17 differentiated 
cells and western blot of activated Notch1 was performed in these lysates. Two 
fold increase in Notch1 expression levels was observed in Th17 differentiated 
cells even at 24hr time point as compared to Th0 cells (Fig.8). Upregulation (5.3 
fold) of Notch1 expression was even observed in naïve T cells stimulated with 
anti-CD3/CD28 stimulus (Th0) as compared to unstimulated cells (Fig.8). This 
supports the previously published data (Palaga et al., 2003) that activation of T 
cells results in upregulation of Notch signaling. Expression of other isoforms of 
Notch (Notch 2, 3 and 4) was also tested, but no significant increase in their levels 
was observed in Th17 differentiated cells as compared to Th0 (Fig.9). 
Upregulation of Notch1 was also observed in extended culture of Th17 cells 
(Fig.10). Real time PCR of Notch downstream target Hey1 was also performed in 
in vitro Th17 differentiated cells to check the activation of Notch signaling.  Seven 
fold increase (p≤0.01) in Hey1 transcript levels were observed in Th17 
differentiated cells as compared to Th0 cells (Fig.11). Thus expression of Notch1 
as well as activation of Notch target gene Hey1 correlates with human in vitro 
Th17 differentiation.  
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Figure 8: Expression of active Notch1 is increased in in vitro Th17
differentiated cells as compared to Th0 and unstimulated naïve T cells.
A) Whole cell lysates were prepared from naive CD4+ T cells un-stimulated
(US), or differentiated under Th0 and Th17 conditions and immunoblotted for
intercellular active Notch1. β-actin was used to confirm equal loading. B)
Densitometry of active Notch1 was performed and nornalized to actin. Data
shown above is plotted as arbitrary units (AU).
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Figure 9: Expression of Notch1, but not Notch2, 3 or 4 favors in vitro
Th17 differentiation. Whole cell lysates were prepared from naive CD4+ T
cells un-stimulated (US), or differentiated under Th0 and Th17 conditions at
indicated time points and immunoblotted for Notch1, Notch2, Notch3 and
Notch4. β-actin was used to confirm equal loading. Lysates from 293T cells
transfected with active Notch1IC, Notch2IC, Notch3IC, and Notch 4IC were used
as positive controls. E: 293T cells transfected with empty vector.
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Figure 10: Expression Notch1 remains elevated at later time points (day 
6 and 7) of  in vitro Th17 differentiation. Whole cell lysates were prepared 
from naive CD4+ T cells differentiated under Th0 and Th17 conditions at 
indicated time points and immunoblotted for Notch1. β-actin was used to 
confirm equal loading. NotchFL: Notch full length, Notch TM: Notch 
transmembrane, NotchIC: intracellular active Notch1, AU: Arbitrary units.
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Figure 11: Upregulation of Notch signaling in in vitro Th17 differentiated cells 
shown by quantitative real time PCR of Notch downstream target gene Hey1. 
Complementary DNA was synthesized from in vitro differentiated Th17 cells and 
Hey1 transcript levels were measured by quantitative real time PCR at 24hrs. Data 
represented here is relative Hey1 transcript levels normalized against 18S and is 
mean SD of two independent experiments performed
in triplicates.**p≤0.01.
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Pharmacologic and genetic knockdown of Notch signaling reduces in vitro human 
Th17 differentiation. 
 Next I examined whether pharmacologic inhibitors of Notch signaling 
pathway could block Th17 differentiation. In vitro Th17 polarization assays were 
used to study the effects of gamma secretase inhibitors (GSI) on naïve CD4+ 
human T cells differentiating towards the Th17 phenotype. Naïve CD4+ T cells 
were pretreated with either DMSO as a vehicle control or individual GSIs 
(Compound E, Z-ILE-LEU-Aldehyde (IL-CHO), Ly 411,575 (LY), DAPT (3,5-
Difluorophenylacetyl)-L-Alanyl-PhenylGlycinebutyl Ester) and cultured for 24-
72hrs in Th17 inducing conditions. IL-CHO is a competitive peptide aldehyde 
inhibitor of γ-secretase activity that is thought to modify the active sites, while 
compound E is a non-peptide, non-transition state, non-competitive inhibitor of γ-
secretase. LY 411,575 and DAPT are chemically similar to compound E. A 
significant reduction in IL-17 secretion was observed after treatment with GSIs at 
24hrs (Fig. 12). Similar reduction in IL-17 levels was observed at 48 and 72 hrs 
after GSI treatment (data not shown). Levels of other Th17 cytokines, including 
IL-17F and IL-22, after GSI treatments were assessed by ELISA. Statistically 
significant decrease (approximately 2 fold) in IL-17F and IL-22 cytokines was 
observed after IL-CHO and compound E treatment (Fig.13). MTS assay was 
performed to confirm a decrease in IL-17A, IL-17F and IL-22 secretion by GSI 
was not due to an effect on cell viability and I observed no change (Fig.14). Next 
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I checked if Notch signaling inhibition affects already differentiated Th17 cells. 
Interestingly, addition of GSI after 5 days of Th17 differentiation did not change 
IL-17A, IL-17F and IL-22 cytokine levels suggesting Notch signaling plays role in 
initial time points of Th17 differentiation process (Fig.15) 
 Thus, I concluded that blocking Notch signaling pathway by gamma 
secretase inhibitors decreases Th17 polarization. This suggests a role of Notch 
signaling in Th17 differentiation, however GSI has several targets besides Notch, 
for example CD44, β amyloid, E-cadherin, ErbB-4. Therefore I planned to 
perform specific knockdown of Notch1 and study its effects on Th17 
differentiation. 
 
Specific knockdown of Notch 1 by siRNA in human naïve CD4+ T cells followed 
by Th17 polarization leads to decreased IL-17 secretion. 
 I observed upregulation of Notch signaling, particularly Notch1 and Hey1, 
in human in vitro Th17 differentiation assays, and GSI inhibited Th17 
differentiation. To determine whether Notch1 is a functional target of GSIs during 
Th17 polarization, expression of Notch1 was reduced by delivery of siRNA to 
naïve CD4+T cells. Naïve CD4+ T cells were nucleoporated with scrambled and 
Notch1 specific siRNA. Cells were subsequently polarized to the Th17 lineage 
and harvested 48 h after transfection. Western blot analysis of Notch1 protein 
and quantitative RT-PCR confirmed that Notch1 siRNA reduced the expression 
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of Notch1 protein (Fig.16A) as well as mRNA (Fig.16B). Western blot of Notch 2, 
3 and 4 expression was also performed to confirm the specificity the siRNA for 
Notch1 (Fig.17) and no significant change were observed in levels of other 
Notches after Notch1 knockdown. Notch1 knockdown (40-50% as compared to 
scrambled siRNA) significantly inhibited IL-17A production (50%, p≤0.05) under 
Th17 polarizing conditions (Fig.16C). I also checked levels of other Th17 
cytokines, IL-17F and IL-22, after siRNA mediated Notch1 knockdown. I 
observed that similar to IL-17A, IL-17F cytokine production was also significantly 
reduced by 50% (p≤0.05) after Notch1 knockdown in human in vitro 
differentiation assay (Fig.18A). Surprisingly I did not observe any significant 
change in IL-22 cytokine production (Fig.18B). Taken together GSI and Notch1 
siRNA data, it seems that IL-22 expression is regulated by other paralog of 
Notch, but not Notch1. Next I checked cell viability of Th17 cells in Notch1 siRNA 
treated cells to assess if decrease in IL-17A and F was due to decrease in cell 
survival.  MTS assays were performed to check cell survival and it revealed no 
changes in viability between cell treated with scrambled siRNA or Notch1 siRNA 
(Fig.16D).  
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Figure 12: Gamma secretase inhibitors (GSIs) significantly reduce IL-17
levels in human in vitro Th17 polarization assays. (A) Semi quantitative RT-
PCR of Hey1 and Hes5 showing GSI mediated down regulation of Notch
signaling. (B)ELISA of IL-17 in supernatants of Th17 polarized naïve human CD4+
T cells treated with GSIs. Purified human CD4+ T cells were pretreated with
indicated concentration of GSIs or DMSO as a vehicle control and then cultured in
Th0 and Th17 polarizing conditions. Supernatants were collected at 24 hrs and
were analyzed for IL-17. Mean SD of two experiments performed in triplicates.
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Figure 13: Gamma secretase inhibitors (GSIs) significantly reduce IL-17F
and IL-22 levels in human in vitro Th17 polarization assays. ELISA of IL-17F
(A) and IL-22 (B) in supernatants of Th17 polarized naïve human CD4+ T cells
treated with indicated concentration of GSIs at 24-72 hrs. Purified human CD4+ T
cells were pretreated with indicated concentration of GSIs or DMSO as a vehicle
control and then cultured in Th0 and Th17 polarizing conditions. Supernatants
were collected at 24, 48 and 72 hrs and were analyzed for IL-17F and IL-22. Data
represented the mean±SD of two experiments performed in triplicates.*p≤0.05,
**p≤0.01.
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Figure 14: MTS assay to assess cell viability of in vitro differentiated Th17
cells. Cells were assayed for viability after GSI treatment using MTS assays.
Data depicted here is absorbance of formazan product (which measures
reductase expressed by viable cells) measured at 490nm using ELISA plate
reader, representing viability of the cells.
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Figure 15: GSI treatment after 5 days of in vitro Th17 differentiation does
not affect IL-17F and IL-22 cytokine levels. ELISA of IL-17F (A) and IL-22 (B)
in supernatants of Th17 differentiated naïve human CD4+ T cells treated with
2μM IL-CHO after 5days of invitro Th17 differentiation. Supernatants were
collected at 24hrs after ILCHO treatment and analyzed for IL-17F and IL-22.
Data shown represent the is mean±SD of two experiments performed in
triplicates.
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Figure 16: Notch 1 controls human Th17 polarization. 107 purified human
naïve CD4+ T cells were nucleoporated with Notch1 specific siRNA or scrambled
siRNA. After transfection, the cells were cultured under Th17 skewing conditions
and whole cell lysates and cDNA were prepared. (A) Immunoblot of Notch1
expression and β-actin (loading control). (B) Quantitative RT-PCR using Notch1
specific primers to assess Notch1 transcript levels.(C) ELISA of IL-17 was
performed on the supernatants of naïve CD4+ T cells nucleoporated with control
siRNA and Notch1 siRNA followed by in vitro Th17 polarization. (D) Cells were
assayed for viability after nucleoporation using MTS assay. Data depicted here
represent absorbance at 490nm, representing relative viability using ELISA plate
reader. Data shown is mean±SD of three independent experiments done in
triplicates.*p≤0.05
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Figure 17: Knockdown of Notch 1 by siRNA does not affect other Notch
isoforms. Western blot of Notch1IC, Notch2IC, Notch3IC and Notch4IC after
nucleoporation of Notch1 siRNA in naïve CD4+ T cells followed by Th17
differentiation. 293T cells transfected with Notch1IC, Notch2IC, Notch3IC and
Notch4IC constructs were used as a positive control.
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Figure 18: Notch 1 controls IL-17F, but not IL-22 cytokine expression in
human in vitro Th17 polarization. Naïve CD4+ T cells were nucleoporated with
Notch1 specific siRNA or scrambled siRNA. After transfection, the cells were
cultured under Th17 skewing conditions and supernatant was collected. ELISA of
IL-17F (A) and IL-22 (B) was performed on these supernatants. Data shown
represent mean ±SD of three independent experiments performed in
triplicates.*p≤0.05
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Overexpression of Notch 1 by retrovirus resulted in increase in human in vitro 
Th17 differentiation. 
 The role of Notch1 in human Th17 differentiation was confirmed by over-
expressing activated Notch1 (intracellular domain of Notch1 cloned in the LZRS 
retroviral construct) in naïve human CD4+ T cells followed by Th17 polarization. 
Western blot of Notch1 was performed to confirm Notch1 over-expression 
(Fig.19A). Naïve CD4+ T cells overexpressing Notch1IC LZRS produced higher 
levels of IL-17A compared to control cells in Th17 differentiation conditions (Fig. 
19B). Interestingly Notch1 overexpression also increased IL-17 secretion in cells 
activated under Th0 conditions, suggesting that Notch1 is a necessary signal to 
promote IL-17 secretion even in the absence of differentiating cytokines and the 
presence of differentiating cytokines during Th17 polarization enhances its effect. 
 
Assessment of Notch Ligands in human Th17 differentiation. 
 
 The presence of Notch ligands (DLL-1, DLL-3, DLL-4, Jag1 and Jag2) 
were assessed by quantitative real time PCR in Th0 and Th17 differentiated cells 
(Fig.20). My preliminary results suggest that transcripts of Notch ligands are 
present on naïve CD4+ T cells. Upon in vitro Th17 differentiation, there is 
upregulation of DLL-1 and DLL-4, and downregulation of Jagged 1 and 2 
transcript levels (Fig.20, 21). 
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Figure 19: IL-17 release by naïve CD4+ T cells in response to Notch 1IC
expression in naïve CD4+T under in vitro Th17 differentiation condition. (A)
Immunoblot of Notch1IC after transduction of naïve human CD4+ T cells with
Notch1ICLZRS or control LZRS followed by Th17 differentiation. (B) ELISA of IL-
17 performed after naïve CD4+T cells transduced with control LZRS and Notch IC
LZRS followed by Th17 differentiation. The data is representative of three
independent experiments performed is triplicates. * p≤.05.
A B
68 
 
 
 
 
  
A B
0
1
2
3
4
5
6
4hrs 12hrs 24hrs
Unstimulated
Th0
Th17
D
L
L
-1
 r
e
la
ti
v
e
 t
ra
n
s
c
ri
p
t 
le
v
e
ls
0
0.4
0.8
1.2
1.6
4hrs 12hrs 24hrs
Unstimulated
Th0
Th17
D
L
L
-3
 r
e
la
ti
v
e
 t
ra
n
s
c
ri
p
t 
le
v
e
ls
0
5
10
15
20
25
4hrs 12hrs 24hrs
Unstimulated
Th0
Th17
D
L
L
-4
 r
e
la
ti
v
e
 t
ra
n
s
c
ri
p
t 
le
v
e
lsC
Figure 20: Upregulation of Notch ligand DLL-4 and DLL-1 correlates with in-
vitro Th17 differentiation. RNA was prepared from naive CD4+ T cells un-
stimulated (US), or differentiated under Th0 and Th17 conditions at indicated
time points and quantitative reverse transcriptase PCR for Notch ligands DLL1
(A), DLL3 (B) and DLL4 (C) was performed. Data represented here is relative
Notch ligand transcript levels normalized against 18S. Data are representative of
two independent experiments performed in triplicates.
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Figure 21: Downregulation of Jagged-1 correlates with in vitro Th17
differentiation. RNA was prepared from naive CD4+ T cells un-stimulated (US),
or differentiated under Th0 and Th17 conditions at indicated time points and
quantitative real time PCR for Notch ligands Jagged-1(A) and Jagged-2(B) was
performed. Data represented here is relative Notch ligand transcript levels
normalized against 18S. Data is representative of two independent experiments
performed in triplicates.
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Discussion 
 Several studies have highlighted the importance of the Th17 subset in 
normal immune responses as well as disease pathology, for example in 
autoimmune disorders and in inflammatory diseases. In this aim I examined the 
regulation of Th17 subset differentiation. The role of Notch signaling in peripheral 
T cell differentiation, particularly of the Th17 subset differentiation, has been 
implied recently, although the clear mechanism has not been clarified (Jurynczyk 
et al., 2008b; Mukherjee et al., 2009). Here I have shown that Notch signaling 
regulates in vitro human Th17 differentiation. Upon in vitro differentiation of naïve 
CD4+ T cells towards the Th17 subset, there is upregulation of activated Notch 1 
expression and of downstream Notch target gene Hey1 transcript levels. Using 
pharmacologic Notch signaling inhibitors as well specific Notch1 siRNA, I have 
demonstrated that Notch signaling, is involved in human Th17 differentiation.  
 Upon in vitro differentiation of naïve human CD4+ T cells towards Th17, 
there is an upregulation of IL-17A, IL-17F and IL-22 production as measured by 
ELISA. Also, real time PCR of ROR-γt and intracellular staining of IL-17 showed 
that these cells are successfully differentiated to Th17 subset. Surprisingly I 
observed insignificant levels of IL-21, another cytokine which is known to be 
produced by Th17 subset.  It may be possible that in humans, IL-21 is not the 
major cytokine produced by Th17 cells whereas in mouse there are significant 
levels of IL-21 secreted by Th17 cells (Wei et al., 2007). This differential 
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production of IL-21 in mouse and humans Th17 cells is very interesting and a 
potential area of future investigation.  
 Using pharmacological inhibitor of γ-secretase in vitro, I have shown that 
loss of Notch signaling resulted in down-regulation of IL-17A, IL-17F and IL-22 
produced by Th17 cells. Because GSI blocks activation of all four Notch proteins, 
experiments described here implicate role of Notch signaling in Th17 
differentiation, but do not determine which unique Notch receptor/s are crucial for 
this process. There are several other potential targets of GSI within the immune 
system. In addition to Notch, CD43 and CD44 are also known to be cleaved by γ-
secretase (Kopan and Ilagan, 2004). Therefore the interpretation of data 
obtained using only GSI can be inconclusive. Therefore I performed specific 
knockdown of Notch1 in naïve CD4+ T cells followed by differentiating them 
towards the Th17 subset. Notch1 siRNA in naïve CD4+ T cells led to 50-60% 
decreased Notch1 expression levels as compared to scrambled siRNA measured 
by real time PCR, however no differences were observed in Notch2, 3, and 4. 
Upon knockdown of Notch1, there is decrease in IL-17A and IL-17F but not IL-
22. Taking together both GSI and Notch1 siRNA data, it seems Notch signaling 
regulates IL-22, but may be Notch1 independent and depend on other Notch 
paralogs. Indeed in Notch1 deficient mice there is no change in IL-22 production 
(Alam et al., 2010). Recently role of Notch2 in regulation of IL-22 secretion has 
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been reported (Alam et al., 2010). It may be possible that different Notch 
receptors regulate IL-17 versus IL-22 cytokine production.  
 Another area of active investigation is the role of Notch ligand in Th17 
differentiation. It has been suggested that different Notch ligands expressed on 
APCs drive differing T cell responses (Amsen et al., 2004). Data from several 
laboratories suggest that antigen presenting cells (APCs) expressing Delta like-4 
(DLL-4) drive the differentiation of Th1 cells (Kassner et al., 2010; Liotta et al., 
2008; Skokos and Nussenzweig, 2007) while APCs expressing Jagged1 promote 
differentiation of Th2 cells (Liotta et al., 2008). Lukacs and colleagues 
(Mukherjee et al., 2009) recently revisited and expanded this observation and 
determined that DLL4 expression is induced on APCs by pathogen-associated 
signals and this ligand promotes expression of ROR-γt and expansion of Th17 
CD4+ T cells. These studies have raised the interesting possibility that distinct 
ligands may initiate different Notch responses in peripheral T cells. My 
preliminary results suggest that Notch ligands are present on naïve CD4+ T cells 
and upon Th17 differentiation; there is upregulation of DLL-4 and together with 
downregulation of Jagged1 transcript levels even after 4hrs as measured by real 
time PCR. This is an interesting finding as Notch ligands are known to be present 
only on antigen presenting cells. Role of these ligands in Th17 differentiation has 
to be further evaluated by knockdown techniques.  
73 
 
 
 
In this aim I have shown the role of Notch signaling, particularly by Notch1, in 
regulating Th17 differentiation. Next I studied the molecular mechanism by which 
Notch regulates Th17 differentiation and whether blocking the Notch signaling 
pathway by GSI is capable of inhibiting Th17 mediated diseases.
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CHAPTER III 
 
NOTCH FUNCTIONS AS A REGULATOR OF ROR-γt AND IL-17 PROMOTER 
Introduction 
ROR-γt (Retinoic acid related orphan receptor-γt) is a member of the 
Retinoic acid receptor related orphan nuclear receptor family. The family consists 
of RORα, RORβ and RORγ differing in chromosome location, function and 
regulation (He, 2002). Due to the use of alternate promoter and exon splicing, 
each member of this family exists in several isoforms differing in tissue 
distribution and function. The RORγ gene map to 1q21.3 and has two isoforms, 
γ1 and γ2 (Hirose et al., 1994). RORγ1 is present in liver, adipose and skeletal 
muscles whereas RORγ2 (ROR-γt) is exclusively present in the cells of immune 
system (Eberl et al., 2004). Initially ROR-γt is shown to be crucial for LTi 
(lymphoid tissue inducer) expressing cells and thus explains the absence of 
lymph nodes and Peyers patches in ROR-γt deficient mice (Eberl et al., 2004). 
The role of ROR-γt in Th17 differentiation was revealed later, when expression of 
this transcription factor was observed in the lamina propria T lymphocytes that 
produce IL-17, whereas and these CD4+IL-17+ T cells were absent in ROR-γt 
deficient mice (Ivanov et al., 2006).  
The ROR-γt transcription factor is found to be induced in human and mice 
Th17 in vitro differentiation assays (Ivanov et al., 2007). Studies have shown that 
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cocktails of IL-6+TGF-β (Ivanov et al.,2007) or IL-6+TGFβ+IL-21+IL-1β (Manel et 
al., 2008) upregulate the transcript levels of ROR-γt in purified CD4+ T cells of 
mouse and human origin respectively prior to expression of IL-17. Furthermore, 
Th0 cells (precursor T helper) isolated from ROR-γt deficient mice failed to 
differentiate towards Th17 and this defect can be rescued by overexpression of 
ROR-γt in these cells (Yang et al., 2008b). ROR-γt transcription factor binding 
site AGGTCA preceeded by 5bp of A/T rich sequence is present within IL-17A, 
IL-17F and IL-23R promoters, and thus it directs the expression of inflammatory 
cytokines (Jetten et al., 2001). Subsequently RORα is also been shown to play 
role in Th17 differentiation (Yang et al., 2008b). Although both ROR-γt and RORα 
regulate Th17 differentiation but ROR-γt is considered to be major player as 
ROR-γt deficiency has more pronounced effect on Th17 differentiation than 
RORα. 
There are very few studies performed on regulation of ROR-γt promoter. A 
recent study suggests that Notch ligand DLL4 regulates expression of ROR-γt 
and thus Th17 differentiation (Mukherjee et al., 2009). They have demonstrated 
that various TLRs upregulate Notch ligand DLL4 in antigen presenting cells 
which binds to CSL on ROR-γt and IL-17 promoter in mouse CD4+ T cells. 
However binding of CSL to these promoters in response to TLR signals does not 
make sense as CSL is usually bound to Notch regulated promoters and provide 
repressive signals. Binding of the intracellular domain of Notch to CSL leads to 
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recruitment of several coactivators including Mastermind and histone 
acetyltransferases, and thus CSL becomes part of transcriptional activator 
complex. In the current aim, I studied the molecular mechanism by which Notch 
regulates human Th17 differentiation process and whether human ROR-γt and 
IL-17 promoters are direct transcriptional targets of Notch. 
 
Results 
Notch1 regulates Th17 polarization by regulating ROR-gammaT promoter.   
I utilized in vitro Th17 differentiation assay to study the mechanism by 
which Notch signaling regulates Th17 differentiation. First key candidate is the 
orphan nuclear receptor ROR-γt, the key transcription factor that orchestrates the 
differentiation of the Th17 effector cell lineage. To determine whether Notch1 
influences human Th17 polarization by regulating ROR-γt expression, naïve 
human CD4+ T cells were purified, and nucleoporated with Notch1 specific siRNA 
and scrambled siRNA as a control, followed by culture under Th17 polarizing 
conditions. Quantitative RT-PCR of ROR-γt was then performed. Notch1 
knockdown resulted in 40% decreased levels of ROR-γt transcripts (Fig. 22A). 
Results from the collaborative laboratory of Dr. Barbara Osborne also 
corroborated my data by showing that GSI treatment down regulates ROR-γt 
transcripts to around 50% in mouse CD4+ T cells as quantified by real time PCR 
in Th17 differentiated cells (Fig. 22B). Taken together, these data indicated that 
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Notch1 regulates the expression of ROR-γt. Further, I explored the possibility that 
Notch1 may directly bind and regulate the human ROR-γt promoter. The human 
ROR-γt promoter was analyzed for putative CSL binding sites by TF-binding 
search software (cbrc.jp/research/db/TFSEARCH.html).Two potential CSL sites 
were identified within the proximal 3kb promoter, upstream of the ROR-γt 
transcriptional start site: CSL1 (-1156 to -1161bp) and CSL2 (-1800 to -2082bp) 
(Fig.23A). Chromatin immune-precipitation analysis (ChIP) using an anti-human 
Notch1 antibody was performed after 24hrs of Th17 in vitro polarization assays to 
determine whether Notch1 binds directly to the ROR-γt promoter.  ChIP 
experiments indicated that Notch1 binds directly to putative CSL binding sites in 
the human ROR-γt promoter (Fig.23B, C).  In particular, Notch1 bound at the 
CSL1 site, which could be inhibited by treatment with GSI (Fig 23B, C). 
Quantitative real time PCR of ChIP assays suggested that Notch1 is recruited to 
human ROR-γt CSL1 site even under Th0 condition (2.5 fold), and Notch1 
recruitment is further increased to around 9 fold under Th17 driving condition. 
This suggests that Notch1 binds the ROR-γt promoter and may be one of the 
mechanisms by which it regulates Th17 differentiation. 
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Figure 22: Notch 1 regulates ROR-γt promoter activity. (A) Human naïve
CD4+ T cells (1x 107) were nucleoporated with Notch 1 specific siRNA or
scrambled siRNA followed by in vitro Th17 polarization. Cells were harvested
and ROR-γt expression was determined by quantitative RT-PCR. Transcript
abundance was normalized to 18s rRNA expression. Data shown represent the
mean±SD for three independent experiments.
(B) In vitro IL-CHO treatment down-regulates ROR-t and IL-17 mRNA
expression. Total RNA was isolated from mouse CD4+ T cells pretreated with
25μM IL-CHO or DMSO as a vehicle control and cultured in Th17 polarizing
conditions and analyzed by quantitative real time PCR.
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Figure 23: Notch 1 binds to the human ROR-γt promoter.(A) Schematic
representation of putative CSL binding sites in human ROR-γt promoter. (C)
Specific primers were used to amplify putative CSL binding sites on the human
ROR-γt promoter. ChIP assay was performed to determine recruitment of Notch1
on ROR-γt promoter. Data shown represents fold recruitment of Notch1 on CSL
binding sites of the human ROR-γt promoter with respect to control IgG
normalized with 1% input DNA. (B) Regular PCR was also performed using
specific primers against CSL sites in ROR-γt promoter to confirm transcript size.
Data represents mean± SD of two independent experiments performed in
triplicates. **p≤.01.
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Notch 1 regulates human IL-17 promoter activity. 
  
 Recent study by Lukacs and colleagues suggested that Notch ligand DLL4 
can regulate the IL-17 promoter and thus Th17 differentiation (Mukherjee et al., 
2009). Additional evidence came from collaborative Osborne Laboratory where 
treatment with GSI led to reduction in IL-17 transcript levels by around 90%. This 
binding of Notch, both to ROR-γt and IL-17 promoter, may be a mechanism by 
which Notch tightly regulates differentiation program such that once fate of naïve 
CD4+ T cells is decided, it is irreversible. Therefore I also checked this possibility 
that Notch may also regulate the IL-17 promoter in addition to the ROR-γt 
promoter. Co-transfection of 293T and Jurkat T cells cells with a human IL-17 
promoter luciferase construct in combination with an activated Notch1 expression 
vector construct (N1IC) resulted 2.5-3 fold increase in human IL-17 promoter 
activity (Fig.24A,B) in both the cell types. This suggests that Notch1 regulates the 
human IL-17 promoter also. Next I assessed if Notch 1 binds directly to human 
IL-17 promoter under in vitro Th17 polarization conditions. The human IL-17 
promoter (3kb) upstream of the transcription start site (TSS) was therefore 
analyzed for putative CSL binding sites (cbrc.jp/research/db/TFSEARCH.html) 
(Fig. 25A). I found four putative CSL binding sites within this region: CSL1 (-167 
to -172bp), CSL2 (-454 to-459 bp), CSL3 (-1210 to-1215 bp) and CSL4 (-1725 to 
-1730 bp) (Fig. 25B). ChIP assays were performed using anti-Notch1 antibody 
after 24 hrs of in vitro Th17 differentiation. The ChIP assays revealed that Notch1 
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binds to putative CSL binding sites in the human IL-17 promoter, particularly at 
CSL1 and 4 (Fig. 25C), but not at CSL 2 and 3.  The binding was inhibited by 
treatment with GSI (Fig.25C). These data suggests binding of both ROR-γt and 
IL-17 promoters, by Notch1. 
  
Differential upregulation of Notch isoforms under in vitro Th1, Th2 and Th17 
differentiation. 
 Although several studies are performed studying the role of Notch 
signaling in peripheral T-helper cells differentiation, particularly Th1 and Th2 
differentiation, concrete conclusions could not be withdrawn. I used human Th1, 
Th2 and Th17 in vitro differentiation assays to address this question. Upon 
human in vitro differentiation of naïve CD4+ T cells towards Th1, Th2 and Th17, 
differential upregulation of Notch isoforms was observed (Fig.26). Expression of 
Notch1 was found to be increased in Th17 differentiation and Notch3 expression 
in Th1 differentiation. This is very interesting as different Notch paralogs can 
regulate T helper cell differentiation to Th1, Th2 or Th17. In addition even the 
expression of individual Notch paralog was found to be different in each T helper 
subset. 
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Figure 24: The human IL-17 promoter is regulated by Notch1. (A) 293 T cells
were co-transfected with intracellular activated Notch expression vector construct
(Notch1IC) along with a human IL-17 promoter construct cloned upstream of the
firefly luciferase gene along with renilla luciferase plasmid. Luciferase assay was
performed and data was normalized to renilla luciferase depicted as relative
luciferase units (RLU). Immuno-blotting of Notch1 was performed to confirm
overexpression. Results are shown as mean±SD of three independent
experiments performed in triplicates.*p≤0.05
(B) Jurkat T cells were electroporated with separate plasmids encoding Notch1IC
expression vector and human IL-17 luciferase promoter. After 48hrs, cells were
stimulated with PMA/I for 6hrs and luciferase assays were performed. Data
shown here is normalized to renilla luciferase and depicted as relative luciferase
units (RLU). Experiments are done in triplicates and data shown is mean±SD of
two independent experiments.
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Figure 25: Notch 1 binds to human IL-17 promoter (A) Schematic 
representation of putative CSL binding sites in human IL-17 promoter. (C) ChIP
assays were performed to determine the recruitment of Notch1 on human IL-17 
promoter. Data shown represents fold recruitment of Notch1 to the human IL-17 
promoter with respect to isotype control IgG normalized to input DNA. (B) PCR 
performed using specific primers against different putative CSL binding sites in 
human IL-17 promoter. Data shown here represents the mean± SD of two 
independent experiments performed in triplicates.*p≤.05,**≤0.01
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Figure 26: Differential upregulation of Notch isoforms under in vitro
Th1, Th2 and Th17 differentiation. Naïve human CD4+ T cells were in vitro
differentiated towards Th1 , Th2 and Th17 subsets. (A) ELISA of Th1
associated cytokine (TNFα), Th2 associated cytokine (IL-5) and Th17
associated cytokine (IL-17A) was performed.(B) At 72 hrs, whole cell lysates
were made and western blotting was performed for active Notch1 and active
Notch3. β actin was used as a loading control. Data depicted here is a
representative of two independent experiments.
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Discussion: 
 
T-helper cells differentiation is a highly regulated process involving several 
molecular events to determine the fate of naïve CD4+ T cells. In this study, I 
assessed the role of the Notch signaling pathway in Th17 differentiation. I 
provided evidence that Notch1 binds and regulates both ROR-γt and IL-17 
promoter providing a mechanism by which Notch1 dictates Th17 differentiation.  
A recent publication has shown that in response to LPS signal, there is secretion 
of IL-17 which can be blocked by antibody to Delta like ligand-4 (DLL-4) 
(Mukherjee et al., 2009). Furthermore addition of DLL-4, but not jagged 1, 
promotes Th17 differentiation. In my in vitro Th17 differentiation, I observed 
increase in DLL-4 transcripts from 5 folds to 12 folds at 12 and 24 hrs 
respectively after Th17 polarization (Fig.20). Combining all the results together, it 
seems that Notch1-DLL-4 signal regulates Th17 differentiation. 
 Previous studies showed a paradoxical role of Notch in differentiation of 
both the Th1 and Th2 CD4+ T cells subsets. Next important question to be 
answered is how Notch signaling dictates mutually exclusive Th1, Th2 and Th17 
differentiation program? Expression of Notch1 was found to be increased in Th17 
differentiation and Notch3 expression in Th1 differentiation. In addition even the 
expression of individual Notch paralog is different in each T helper subset. 
Knockdown of individual Notch receptor as well as expressing Notch receptors in 
varied levels would further resolve this issue. 
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Notch binds and regulates the T bet and IFNγ promoters during Th1 
differentiation, and GATA3 and IL-4 promoter in Th2 differentiation (Amsen et al., 
2007; Minter et al., 2005). In this study I have shown that Notch1 can also bind to 
ROR-γt and IL-17 promoter in Th17 differentiation. It is possible that Notch 
promiscuously binds to promoters defining more than one differentiation pathway 
or there is difference in co-activator complex which is recruited to these 
promoters resulting in differential T helper cell differentiation pathways. It has 
been shown that coactivator Mastermind 3 (MAML3) has high Notch 4 binding 
preference in contrast to MAML1 which favorably binds Notch3 (Wu et al., 2002).  
Further, it has also been shown that Notch binds as a dimer to c-myc and pre 
TCR promoter (Liu et al., 2010). Interestingly in both human ROR-γt and T-bet 
promoter, I observed two adjacent putative Notch binding sites. Another 
assumption can be that combination of different Notch paralogs result in 
differential T helper cell differentiation. Further experiments have to be performed 
to assess these assumptions. 
 Till now, I have demonstrated the role of Notch as an important 
determinant of Th17 differentiation under in vitro conditions. Next I studied the 
biological significance of Notch signaling in Th17 mediated autoimmune disease. 
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CHAPTER IV 
NOTCH SIGNALING INVOLVEMENT IN TH17 MEDIATED DISEASE, EAE 
(EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS), MOUSE MODEL 
OF MULTIPLE SCLEROSIS 
 
Introduction 
  EAE (Experimental autoimmune encephalomyelitis) is an animal model 
that resembles human inflammatory demyelinating disease, Multiple Sclerosis 
(MS) (Sospedra and Martin, 2005). Histologically MS is characterized by 
presence of inflammatory T cells and macrophages in active lesions 
accompanied by demyelination, loss of oligodendrocytes and axonal damage. 
This damage to the myelin sheath hampers neuronal transmission and causes 
debilitating symptoms in MS patients including loss of sensation, muscle 
weakness, visual impairment and paralysis (Compston and Coles, 2002; 
Compston and Coles, 2008). The symptoms of MS can be broadly divided into 
two subtypes: relapsing-remitting or progressive disease. The relapsing-remitting 
type is characterized by the presence of disease symptoms alternating with 
asymptomatic periods. Progressive disease is marked by continuous 
neurological symptoms without remission (Lublin and Reingold, 1996). This 
disease usually affects young adults, most commonly females, with a frequency 
of 2-150 per 100,000 (Rosati, 2001). There is no known cure for MS. Current 
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regimens aims to prevent new attacks and stabilizing patients (Compston and 
Coles, 2002). 
  In mice this disease is induced by injecting brain extracts, CNS proteins 
(Myelin basic protein) or small molecule derivative of CNS proteins (Proteolipid 
peptide, Myelin oligodendrocyte glycoprotein) emulsified in complete Freund’s 
adjuvant (CFA) (Mannie et al., 2009; Miller and Karpus, 2007). The presence of 
adjuvant facilitates the generation of an inflammatory response towards CNS 
proteins. Along with CFA, mice are also injected with pertussis toxin which helps 
break the blood brain barrier and allows immune cells to attack the CNS (Miller 
and Karpus, 2007). 
 Classically EAE was considered to be a Th1 mediated disease with a 
predominant role for IFNγ (Kuchroo et al., 2002). Later, this paradigm was 
challenged and systematic studies utilizing mice knock-out for IL-12p19 and IL-
23p35 subunits revealed that indeed IL-23, but not IL-12, is important for EAE 
development (Cua et al., 2003; Langrish et al., 2005; Langrish et al., 2004). IL-23 
is an indispensable cytokine for Th17 development, that is required for 
maintenance and expansion of this subset (Harrington et al., 2005). 
Subsequently several studies were performed to study role of Th17 subset in 
EAE pathogenesis. Two photon microscopy of the brainstem of mice having 
progressive EAE showed a direct interaction between Th17 cells and neurons, 
which leads to an intracellular Ca2+ imbalance and damage to neuronal cells 
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(Siffrin et al., 2010). Moreover, with co-culture experiments between glial cells 
and autoreactive T cells it was shown that T cells secreting IL-17 are responsible 
for inducing an inflammatory milieu with in CNS. IL-17 also promotes neuronal 
inflammation by inducing MHC class II and costimulatory molecule expression on 
glial cells (Domingues et al., 2010). Recent studies using adoptive transfer of 
myelin oligodendrocyte glycoprotein (MOG) specific Th1 or Th17 monoclonal T 
cell clones expressing the same TCR into lymphopenic Rag2-/- knockout mice 
revealed interesting results. Rag2-/- knockout mice that received Th1 cells 
develop classical EAE with paralysis progressing from tail to head, whereas 
those receiving Th17 cells develop atypical EAE with an ataxia and an 
unbalanced gait followed by tail to head paralysis. In a cutting-edge article 
utilizing IL-17A fate reporter mice (Il17aCreR26ReYFP) it was shown that under 
chronic inflammatory conditions in EAE, Th17 cells switch to an IFNγ producing 
phenotype, again supporting a role for Th17 cells in EAE pathogenesis (Hirota et 
al., 2011).  
  Since my in vitro experiments have demonstrated the role of Notch 
signaling in regulating Th17 differentiation, therefore I hypothesized that Notch 
inhibitors can prevent Th17 mediated diseases. Besides Notch signaling 
regulating human Th17 differentiation, parallel data have been obtained in mouse 
Th17 differentiation assays in Dr. Osborne laboratory, University of 
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Massachusetts, Amherst. Summary of results obtained in mouse in vitro Th17 
differentiation assays are given below: 
Gamma secretase inhibitors (GSI) significantly down-regulate Th17 
associated cytokine levels in murine Th17 in vitro polarization assays. 
Upregulation of Notch1 in mouse Th17 differentiation assays, which 
decreases upon treatment with GSI. 
Downregulation of intracellular IL-17 levels upon treatment with GSI in 
mouse Th17 differentiated cells. 
 
Combining both mouse and human data led us to check in vivo if Notch inhibition 
ameliorates EAE, a Th17 mediated disease. 
  This work is done in conjunction with Dr Barbara Osborne laboratory, 
University of Massachusetts, Amherst. 
 
Results 
Gamma Secretase inhibitor (GSI) ameliorates the severity of EAE induced 
inflammation and Th17 differentiation in-vivo.  
  To investigate the role of Notch signaling in regulating Th17 mediated 
disease in vivo, we immunized the SJL/J strain of mice with proteolipid peptide 
(PLP) in complete Freund’s adjuvant (PLP139-151-CFA) to induce EAE, a Th17 
dependent chronic autoimmune disease. Before inducing EAE, SJL mice were 
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fed control chow or orally active GSI (LY) chow for 5 weeks. We used doses 
between 2.5 and 5 mg/kg/day of GSI, which is known to be safe and effective in 
reducing Notch activity.  Higher doses cause the secretory diarrhea due to goblet 
cell metaplasia of the intestine. In control mice (fed with normal chow), the initial 
signs of EAE were observed at day eight post immunization. Delayed onset of 
disease, ten days after immunization, was observed in mice fed with Notch 
signaling inhibitor GSI (Fig.27A). This suggested that inhibition of Notch signaling 
by oral GSI delayed the onset of EAE. Next we wanted to check whether Notch 
inhibitors affect the disease symptoms. The progression and severity of EAE 
disease was monitored and scored from 0-5 as follows: Score 0-no disease; 1-
limp tail, 2-hind limb weakness; 3-hind limb paralysis; 4-hind and fore limb 
paralysis; 5-morbidity and death (Serada et al., 2008). We observed that in 
control mice (mice fed with normal chow) the mean clinical score at the peak of 
disease was 2 (hind limb weakness) while in GSI fed mice the clinical mean 
score was reduced to 0.2 (Fig.27A). Therefore GSI treatment delayed the 
disease progression as well as reducing the severity of EAE symptoms. 
  Next we wanted to assess whether this relief of symptoms in EAE disease 
(in SJL/J mice by GSI) was due to an effect on Th17 responses.  Splenocytes 
were obtained from control or GSI fed mice, and were stimulated with PLP 139-151 
in vitro. It was observed that PLP stimulated splenocytes cultured from SJL/L 
mice fed with GSI showed significantly lower (approximately four fold, p<0.05) IL-
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17 levels as compared to control chow fed mice (Fig.27B). Similarly, 
supernatants obtained from mononuclear cells isolated from spinal cords showed 
lower IL-17 levels in the GSI-treated mice than in the control group (Fig.27C). 
This suggested that GSI treatment hampered the potential of immune cells 
among splenocytes, and mononuclear cells within the CNS to elicit Th17 
response towards the PLP peptide. Since Notch signaling is important for T cells 
development also, another possibility is that in GSI fed mice there is reduction in 
total T cell numbers, rather than an effect on Th17 differentiating potential. 
Therefore we quantified staining spinal cord infiltrating cells for CD4+ and CD8+ 
surface markers in GSI fed mice (Fig.28). We observed no significant differences 
between control chow or GSI fed mice in the number of T cells infiltrating the 
spinal cord. This showed that the decrease in IL-17 in the group of mice treated 
with GSI was not due to a difference in infiltrating T cell numbers, but rather due 
to selective effects of GSI on Th17 cells. 
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FIGURE 27: GSI treatment reduces EAE-induced inflammation and the
development of PLP139-151-specific Th17 responses. (A) Clinical scores of
SJL/J mice given GSI formulated chow, at 2.5mg/kg alternated with 5mg/kg for
4 weeks. Control mice were given regular chow. n=5 mice in each group.
Results represent the mean disease score grouping each group. Splenocytes
(B) and cells from the spinal cords (C) of EAE-induced mice were restimulated
ex vivo with PLP139-151 and were then analyzed for IL-17 by ELISA.
By Reem Suleiman, Dr Osborne Laboratory
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FIGURE 28: GSI treatment does not affect total number of CD4 and CD8 T
cells. After feeding SJL/J mice with GSI formulated chow, total spinal cord
cells were stained with CD4 and CD8 antibodies and analyzed by flow
cytometry.
By Reem Suleiman, Dr Osborne Laboratory
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Discussion: 
In this study, we asked whether Notch signaling would influence Th17 
mediated immune responses in vivo. We used the EAE (Experimental 
autoimmune encephalomyelitis) mouse model of the human demyelinating 
disease Multiple Sclerosis. Initially a role for the Th17 subset in autoimmune 
diseases was discovered within this model, leading to several publications 
highlighting the role of the Th17 subset and associated cytokines in the axonal 
damage and demyelination in the EAE model system (Cua et al., 2003; 
Domingues et al., 2010; Hirota et al., 2011). Thus the Th17 subset is considered 
to make a major contribution to EAE pathogenesis. We have shown that Notch 
signaling plays a role in Th17 differentiation using in vitro Th17 differentiation 
assays. Therefore, targeting the Notch pathway in the EAE disease model can 
be an effective means to regulate Th17 differentiation and EAE associated 
symptoms. Interestingly, oral Notch signaling inhibitors GSI were able to delay 
the onset of disease as well as the clinical score of EAE in SJL/J mice. As GSI 
treatment did not impact on the total number of T cells, this suggested that GSI is 
effecting EAE disease progression by altering the inherent ability of T cells to 
differentiate towards Th17 subset.   
The effect of GSI on EAE disease progression can also be partially due to 
role of Notch signaling in Th1 differentiation. The concept that Th17 is the only 
subset responsible for CNS inflammation is challenged by several reports 
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showing that both Th1 and Th17 cells are involved in EAE (Kroenke et al., 2008; 
Stromnes et al., 2008). It has been shown that both ROR-γt and T-bet deficient 
mice are resistant to EAE (Bettelli et al., 2004; Ivanov et al., 2006). Moreover, 
analysis of T cells infiltrating the CNS during EAE development showed presence 
of both Th1 and Th17 cells (Korn et al., 2008; Langrish et al., 2005). Notch is 
already reported to regulate Th1 differentiation and EAE pathogenesis by 
regulating IFNγ levels (Minter et al., 2005). Taken together, Notch inhibitors can 
be an effective therapy against EAE pathogenesis as it regulates both Th1 and 
Th17 proinflammatory subsets. In support of our data, difluroketone MW167, 
another GSI was injected to the lateral cerebral ventricle of mice with EAE, and 
these mice showed enhanced recovery as compared to control mice. In GSI 
injected mice there was decreased inflammation accompanied by remyelination, 
emphasizing that targeting Notch signaling can also be an effective therapy for 
EAE (Jurynczyk et al., 2005). During development Notch negatively regulates 
oligodendrocytes maturation by inhibiting transcription factors Mash1 and 
NeuroD (Lee, 1997). It may be possible that Notch is re-expressed in multiple 
sclerosis/EAE lesions and prevent oligodendrocytes maturation and thus 
remyelination. This could explain restoration of myelination after Notch signaling 
inhibition by GSI treatment.  
LY450139, yet another GSI, is already in Phase II clinical trials to treat 
Alzheimer’s disease, since β-amyloid is another GSI target (Fleisher et al., 2008; 
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Siemers et al., 2005). This drug is found to be well tolerated, with minor side 
effects including drug rashes, hair color changes and gastrointestinal symptoms 
(Fleisher et al., 2008). Thus targeting Notch signaling to treat MS patients by 
GSIs seems to be an attractive therapeutic tool. Other targets, for example 
antibodies against specific Notch receptors or Notch ligand Delta can also be 
used to manipulate Notch signaling more specifically in the treatment of multiple 
sclerosis and autoimmune diseases in general. 
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CHAPTER V 
PUTATIVE ROLE OF NOTCH SIGNALING IN Th1/Th17 DOUBLE PRODUCER 
CELLS. 
 
Introduction 
The Th1-Th2 paradigm introduced by Mosmann and Coffman helped us to 
understand adaptive immunity and the potential of the immune system to acquire 
alternate differentiation program, in response to different pathogenic stimuli. This 
helper CD4+ T cell differentiation program was considered to be mutually 
exclusive and self-reinforcing. The discovery of Th17 has not only further 
extended our understanding of adaptive immunity, but also led us to appreciate 
the non-rigid aspects of the T helper cell differentiation program. The 
identification of TGFβ and IL-6 as important cytokines required for Th17 
differentiation, and ROR-γt as a Th17 lineage determinant transcription factor, led 
to the acceptance of Th17 as a novel and distinct T-helper cell subset (Ivanov et 
al., 2006; Yang et al., 2008b). Nevertheless substantial evidence has since 
accumulated pinpointing to the plastic nature of this subset. Th17 differentiated 
cells readily convert to IL-17+IFNγ+ double positive cells in vitro (Annunziato et 
al., 2007; Bending et al., 2009; Lee et al., 2009; Martin-Orozco et al., 2009a; Shi 
et al., 2008), which may be the reason for the initial supposition that Th17 cells 
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originated from the Th1 subset, rather than being a separate subset (Bettelli and 
Kuchroo, 2005). It was also hypothesized that this Th17/Th1 plasticity only 
occurs in in vitro cultures, but not in vivo, due to the absence of a complete 
cytokine environment providing strong Th17 polarizing signals in culture. This 
was refuted by using an IL-17 reporter system in vivo in which IL-17 producing 
cells cannot only be detected but also traced. Upon induction of EAE by 
immunization with MOG-CFA (Myelin Oligodendrocytes Glycoprotein in 
Complete Freund’s Adjuvant) in  Il17aCreRosa26eYFP mice, eYFP+ (IL-17A 
secreting) cells develop from IFNγ-IL-17A secreting cells to IFNγ+IL-17A+, and 
finally into predominantly IFNγ secreting cells (Hirota et al., 2011). Thus this 
report provides evidence of Th17 cells being plastic even under in vivo disease 
conditions. Furthermore when Th17 differentiated MOG specific CD4+ T cells 
were adoptively transferred to Rag2-/- mice, they spontaneously converted to a 
Th1 phenotype in an EAE model system (Domingues et al., 2010). Similar 
studies have been performed in the autoimmune colitis mouse model (Lee et al., 
2009) and in an adoptive transfer model of diabetes (Bending et al., 2009) 
revealing parallel results of conversion of the Th17 subset to a Th17/Th1 dual 
phenotype and its role in disease pathogenesis. Importantly Th17/Th1 cells are 
also detected in human diseases, for example in inflammatory bowel disease 
(Kleinschek et al., 2009) and rheumatoid arthritis (Nistala et al., 2010). 
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Studies have been performed to understand the mechanism of Th17/Th1 
plasticity. The most important driving factor appears to be the cytokine 
environment. IL-6 and TGFβ up regulate ROR-γt and RORα, which in-turn 
increase expression of the IL-23 receptor and IL-12 receptorβ-2 in Th17 
precursor cells. This may explain the responsiveness of Th17 precursor cells to 
both IL-23 and IL-12 (Lee et al., 2009). Therefore, Th17 precursor cells transform 
from a Th17 to a Th1 phenotype depending upon the balance between cytokines 
with a TGFβ promoting Th17 phenotype, low TGFβ and high IL-23 promoting the 
dual Th17/Th1 phenotype and high IL-12 promoting a Th1 phenotype. IL-23 is 
also been shown to upregulate T-bet in Th17 precursor cells. In this regard IL-
23p19 deficient Il17CreR26ReYFP reporter mice failed to upregulate T-bet after 
MOG-CFA immunization suggesting a role for IL-23 in not only Th17 subset 
development but also in double expression of IL-17 and IFNγ by regulating the T-
bet transcription factor (Hirota et al., 2011). 
The presence of an IL-17+IFNγ+ double positive population both in vitro 
and in vivo in mice and humans, and their role in the pathogenesis of several 
diseases makes Th17 and Th17/Th1 double producers an area of active 
investigation. Studies to resolve the molecular mechanisms underlying the 
differentiation of naïve CD4+ T cells towards Th17 and Th17/Th1 plasticity will 
help to understand adaptive immune responses and their dysregulation in 
autoimmune diseases. In this study I have shown that Notch binds to both ROR-
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γt and IL-17 promoters, consistent with role of Notch signaling in Th17 
differentiation. Previously a role for Notch signaling in Th1 differentiation has also 
been shown (Minter et al., 2005) suggesting that similar signals are involved in 
the polarization towards either subset. Moreover, Notch ligand Delta plays a role 
in both Th1 (Skokos and Nussenzweig, 2007) and Th17 (Mukherjee et al., 2009) 
differentiation, suggesting Notch-Delta interaction play role in co-differentiation of 
Th17/Th1 subsets. Therefore it is very interesting to identify whether Notch 
signaling similarly defines Th17/Th1 plasticity.  
 
Results 
The presence of IL-17+/IFNγ+ double positive cells in human in vitro Th17 
differentiation assay. 
In order to study the role of Notch signaling in Th17/Th1 double producer 
population, I wanted to check if IL-17+/IFNγ+ double positive cells are detectable 
in human in vitro Th17 differentiation assays. Naïve CD4+ T helper cells 
(CD4+CD45RA+) were purified from human peripheral blood mononuclear cells 
and were cultured under Th0 and Th17 polarizing conditions. After 24 hrs, 
supernatants were collected and analyzed for TNFα as a cytokine marker for Th1 
cells by ELISA. In human Th17 in vitro differentiation assays, I observed a two 
fold increase in TNFα levels as compared to Th0, but no changes in IL-5 levels 
were detected (Fig.29). This observation was further confirmed by performing 
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intracellular staining of IFNγ and IL-4 in Th0 and Th17 in vitro polarized subsets 
(Fig.30). I observed that within human in vitro Th17 differentiated subset, there is 
an increase in IL-17+/IFNγ+ expression by 5.6 fold as compared to Th0 as 
detected by flowcytometry, with no change in IL-4 expression. Furthermore 
transcript levels of T-bet were also up-regulated two fold within Th17 
differentiated subset as compared to Th0 as detected by real time PCR (Fig.31). 
Taking together all these results, I concluded that during human in vitro Th17 
differentiation, a mosaic IL-17+/IFNγ+ population is present. Another interesting 
observation is the presence of T-bet transcripts within the Th17 differentiated 
subset. Next I wanted to study role whether Notch signaling also plays a role in 
Th17/Th1 population differentiation. 
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Figure 29: GSI affects Th1 (TNFα) but not IL-5 underTh17 polarization. Naïve
CD4+ T cells were in vitro polarized to Th0 or Th17 and pretreated with different
concentrations of GSI or DMSO as a vehicle control. Supernatants were collected
after 24 hrs and ELISA was performed for Th1 cytokine TNFα (A) and Th2
cytokine IL-5 (B). Concentrations of GSI used were DAPT (10,25,50μM), CompE
(500nm,2μM and 5μM), Ly (10,25,50μM) and IL-CHO (2,5,10μM). Data is
representative of three different experiments done in triplicates. For T test, values
are compared with Th17 ( DMSO).*p≤0.05,**p≤0.01.
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Figure 30: IFNγ+/IL-17+ mosaic population in both Th1 and Th17
differentiated cells. Naïve human CD4+ T cells were in vitro differentiated
towards Th1 and Th17 subsets. Intracellular staining with anti-humanIL-
17PE, anti-human IFNγ-APC and anti-humanIL-4FITC was performed after
72hrs. Cells were stimulated with PMA/Ionomycin for 4hrs and monensin for
further 2 hrs. Cells were then fixed and permeabilized, followed by staining
with aforementioned antibodies and analyzed by flowcytometry.
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Figure 31: Upregulation of T-bet transcripts in in vitro Th17 differentiated cells 
shown by quantitative real time PCR . cDNA was synthesized from in vitro
differentiated Th17 cells and T bet transcript levels were measured by quantitative 
real time PCR at 24hrs. Data shown here represent relative T bet transcript levels 
normalized against 18S transcripts and are mean SD of two independent 
experiments done in triplicates.*p≤0.05.
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Pharmacologic and genetic inhibition of Notch signaling in Th17 differentiation 
reduces Th1 (TNFα) associated cytokines with no change in Th2 (IL-5). 
 In order to study the role of Notch signaling in differentiation of Th17/Th1 
mosaic population, pharmacologic inhibitors of the Notch signaling pathway were 
used.  Naïve CD4+ T cells were pretreated with either DMSO as a vehicle control, 
or individual GSI, namely {Compound E (GSI XXI, (S,S)- 2-[2-(3,5-
Difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-
benzo[e][1,4]diazepin-3-yl)-propionamide), IL-CHO (GSI XII, Z-ILE-LEU-
Aldehyde), Ly (Ly-411575) and DAPT (GSI IX, Ly 374973,(3,5-
Difluorophenylacetyl)-L-Alanyl-PhenylGlycinebutyl Ester)}.  I observed that with 
increasing concentrations of different GSIs, there is significant decrease in levels 
of TNFα (p≤.05) and IL-17A (p≤.05), IL-17F (p≤.05) and IL-22 (p≤0.5) at 24hrs 
with no change in cell viability as measured by MTS assays (Fig.29A,12,13). 
Interestingly I did not observe any change in IL-5 levels even at the highest GSI 
concentrations by ELISA (Fig.29B). This suggested that Notch signaling is 
playing a role in the initial steps of differentiation of both Th1 associated cytokine 
TNFα and Th17 associated cytokines IL-17A, IL-17F and IL-22 in human in vitro 
differentiated Th17 cells. It also suggests that Notch signaling does not regulate 
Th2 associated cytokine IL-5 in human in vitro Th17 differentiation assays. 
However the downside of using GSI is its lack of specificity, exemplified by a 
number of alternate targets including β amyloid, CD44, ErbB-4 and E-cadherin. 
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Therefore the effects of GSI of the Th1 and Th17 subsets can be indirectly due 
effects on other downstream targets. Next I studied the specific role of Notch 
signaling on regulating Th1 and Th17 associated cytokines in Th17 differentiated 
cells.  
 I observed an up-regulation of only Notch1 expression, but not of other 
Notches in human in vitro Th17 differentiated cells, which also contained 
IFNγ+/IL-17+ double positive cells (Fig.9). Therefore I planned to specifically 
knock down Notch1 by siRNA in naïve CD4+ T cells followed by Th17 
differentiation. Naïve CD4+ T cells were nucleoporated with scrambled and 
Notch1 specific siRNA and were subsequently polarized to the Th17 lineage. I 
observed that upon Notch1 downregulation (50% as compared to scrambled 
siRNA), there is a significant decrease in IL-17A (p≤0.5), IL-17F (p≤0.5) and 
TNFα (p≤0.5) levels as measured by ELISA (Fig.32A,16C,18A). Surprisingly, 
Notch1 down-regulation reiterated the same results as GSI treatment, having no 
effect on IL-5. Rather, a statistically significant increase in IL-5 levels was 
observed upon Notch1 knockdown (Fig.32B). This suggested that Notch1 is 
controlling  Th1 and Th17 associated cytokines  as upon downregulation of 
Notch signaling either by chemical inhibitors or Notch1 specific siRNA, it led to a 
decrease in Th1 associated cytokines (TNFα) and Th17 associated cytokines (IL-
17A and IL-17F). Unexpectedly Notch inhibition shifted differentiation program 
towards the Th2 lineage (as I observed an increase in IL-5). It is very surprising 
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as even under Th17 differentiating conditions, the absence of Notch1 can reduce 
the differentiation of naïve CD4+ T cells towards the Th17 lineage while 
promoting IL-5 secretion. 
  I further addressed the role of Notch1 in regulating human Th17/Th1 
mosaic population differentiation by over-expressing activated Notch1 
(intracellular domain of Notch1 cloned into the LZRS retroviral construct) in naïve 
human CD4+ T cells followed by Th17 polarization. Notch1 overexpression led to 
a statistically significant increase in IL-17 levels (p≤0.5) (Fig.19). Although I did 
not observe a statistically significant difference, I did observe a trend towards 
increased TNFα levels. (Fig.33A). No changes were observed in IL-5 cytokine 
levels measured by ELISA (Fig.33B).  
 Therefore I concluded that Notch signaling, particularly by Notch1, is 
regulating Th17 and Th1 populations upon in vitro Th17 differentiation, but not 
Th2. The next important question to be answered is molecular mechanism by 
which Notch1 is regulating the Th17/Th1 double producers. 
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Figure 32: Notch1 knockdown results in a decrease of TNFα and an increase in 
IL-5 levels. Naïve CD4+ Tcells were nucleoporated with scrambled or Notch1 siRNA
followed by in vitro Th17 differentiation. Supernatants were collected after 48hrs. 
ELISA was performed for TNFα (A) and IL-5 (B). Data shown is mean SD of two
different experiments performed in triplicates. *p≤0.05.
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Figure 33: Notch1 overexpression results an increase in TNFα, but no change 
in IL-5 expression upon in vitro Th17 differentiation. ELISA of TNFα (A)and IL-5 
(B) performed after naïve CD4+T cells were transduced with control LZRS and Notch 
IC LZRS followed by Th17 differentiation. Data shown is mean SD of two 
independent experiments performed in triplicates.
A
B
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Notch1 binds and regulates T-bet promoter activity, but not to GATA3 upon in 
vitro Th17 differentiation.   
 To examine the molecular mechanism by which Notch signaling regulates 
Th17/Th1 differentiation, I studied the human T-bet, ROR-γt and GATA3 
promoters and their regulation by Notch1. Firstly I down-regulated Notch1 in 
human naïve CD4+ T cells followed by Th17 differentiation, and quantified 
transcripts encoding T-bet, ROR-γt and GATA3 by real time PCR (Fig.34, 22). I 
observed that upon Notch1 knockdown there is a 50% decrease in T bet 
transcripts (p≤0.05) and a 40% decrease in ROR-γt transcripts (p≤0.05). 
Interestingly, there were no changes observed in human GATA3 transcript levels 
upon Notch1 knockdown. This suggested that Notch1 is regulating T-bet and 
ROR-γt transcription, but not GATA3 in human in vitro Th17 differentiated cells. 
Next I studied regulation of human T-bet promoter by Notch1 in 293T cells. 293T 
cells were co-transfected with a construct encoding human T-bet promoter 
(2.5kb) inserted upstream of renilla luciferase, and an activated Notch1 
expression vector construct. Notch1 induced a 7 fold increase in human T bet 
promoter activity (Fig.35). This suggested that Notch1 regulates expression from 
the human T-bet promoter. Next I assessed regulation of human T-bet, ROR-γt 
(Chapter 3) and GATA3 promoter by Notch1 in vivo. The human T-bet promoter 
(3Kb upstream of transcription start site) was analyzed for putative CSL binding 
site using the TFSEARCH software program (cbrc.jp/research/db/ 
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TFSEARCH.html). Two putative CSL binding sites were found within this region, 
CSL1 (-1732 to -1737bp) and CSL2 (-2478 to -2497 bp) (Fig. 36A). Naïve CD4+ 
T cells were in vitro differentiated towards Th17, and ChIP assays were 
performed after 24 hrs of differentiation. The ChIP assays showed that Notch1 
binds to putative CSL binding site CSL2 within the human T-bet promoter (Fig. 
36B), but not to CSL 1.  The binding was inhibited by pretreatment with GSI 
(Fig.36C). Under the same conditions, a ChIP assay was performed on the 
human GATA3 promoter. The human GATA3 promoter was scanned for putative 
CSL binding sites using TFSEARCH software and two sites were identified: 
CSL1 (-138 to -152 bp) and CSL2 (-1741 to -1746bp). When a ChIP assay was 
performed, Notch1 was not immunoprecipitated with either of these putative CSL 
binding sites within the human GATA3 promoter (Fig.37). Thus these data 
support binding of human T bet and ROR-γt promoter activity by Notch 1, 
consistent with Notch mediated regulation of Th17 and possibly Th17/Th1 double 
producer population. Moreover, Notch1 do not bind to human GATA3 promoter 
under in vitro Th17 differentiating conditions. 
 Thus these results insinuate towards a role for Notch signaling, particularly 
of Notch1, in Th17/Th1 differentiation by binding ROR-γt and T-bet promoters. 
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Figure 34: Decrease T-bet but not GATA3 transcript levels following Notch1 
knockdown. Naïve CD4+ Tcells were nucleoporated with scrambled or Notch1 
siRNA followed by in vitro Th17 differentiation. RNA was isolated and quantitative 
real time PCR was performed for T bet (A) and GATA3 (B). Data shown is mean SD
of two different experiments perfromed in triplicates. *p≤0.05.
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Figure 35: The human T-bet promoter is regulated by Notch1. 293 T cells
were co-transfected with an intracellular activated Notch expression vector
construct (Notch1IC) along with a human T-bet promoter construct cloned
upstream of the firefly luciferase gene. Luciferase assays were performed and
data were normalized to renilla luciferase depicted as relative luciferase units
(RLU). Results are shown as mean±SD of three independent experiments
performed in triplicates.**p≤0.01
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Figure 36: Notch1 binds to human T-bet promoter in in vitro Th17
differentiation. (A) Schematic representation of putative CSL binding sites on
human T bet promoter. ChIP assays were performed to determine the
recruitment of Notch1 on human T-bet promoter. (C) Data shown represents fold
recruitment of Notch1 with respect to isotype control IgG on human T-bet
promoter normalized to input DNA. (B) Regular PCR was also performed using
specific primers against different putative CSL binding sites in human T-bet
promoter to confirm transcript size. Data depicted is representative of two
independent experiment performed in triplicates.*p≤0.05
*
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Figure 37: Notch1 do not bind to human GATA3 promoter under in vitro
Th17 polarization conditions. (A) Schematic representation of putative CSL
binding sites on human GATA3 promoter. (C) Data shown represents fold
recruitment of Notch1 on human GATA3 promoter with respect to isotype control
IgG normalized to input DNA. (B) Regular PCR was also performed (2μl of DNA
eluates) using specific primers against different putative CSL binding sites in
human T-bet promoter to confirm transcript size. Data is repeated two times in
triplicates.
A
B
C
117 
 
 
 
 
  
0
2000
4000
6000
8000
IF
N
γ
(p
g
/m
l)
FIGURE 38: GSI treatment reduces EAE-induced inflammation and the
development of PLP139-151-specific Th1 responses. SJL/J mice given GSI
formulated chow and control mice were given regular chow. n=5 mice in each
group. Splenocytes of EAE-induced mice were restimulated ex vivo with
PLP139-151 and were then analyzed for IFNγ by ELISA.
By Reem Suleiman, Dr Osborne Laboratory
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Figure 39: Differential regulation of Fringes during Th1, Th2 and Th17
differentiation. RNA was prepared from naive CD4+ T cells differentiated under
Th0, Th1, Th2 and Th17 conditions at indicated time points and quantitative real
time PCR for Fringes were performed. Data represented here is relative Fringes
transcript levels normalized against 18S.
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Discussion: 
 In this study I have demonstrated that Notch signaling along with TCR 
activation provides a polarizing signal to naïve CD4+ T cells to adopt a Th17/Th1 
phenotype. By using pharmacologic inhibitors of Notch signaling (GSI) as well as 
specific inhibition of Notch1, I observed that there is a reduction in TNFα and IL-
17 cytokine levels, but no change in IL-5 levels in in vitro differentiated Th17 
cells. Furthermore, down-regulation of Notch1 in naïve CD4+ T cells followed by 
Th17 differentiation resulted in a decrease in T-bet and ROR-γt transcript levels 
but no change in GATA3 transcripts. ChIP assays performed on in vitro 
differentiated Th17 cells have shown that Notch1 binds to human T-bet and 
ROR-γt promoter but not to the GATA3 promoter despite the presence of 
consensus binding sites in all promoter sequences assessed, which contributes 
to our understanding of the molecular mechanism by which Notch1 drives 
Th17/Th1 differentiation. This observation is also valid in vivo as GSI reduces the 
symptoms of EAE , also down-regulating both IL-17 and IFNγ levels (Fig.27.38) 
(Minter et al., 2005). 
 After discovery of Th17, several studies suggested a role for Th17 but not 
Th1 in the pathogenesis of autoimmune diseases including EAE (Cua et al., 
2003). It has been argued that these studies were performed using harsh 
treatments, such as actively immunizing animals with complete Freund’s 
adjuvant that would affect the overall immune response of the animals. Later 
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studies were performed by adoptively transferring polarized Th1 or Th17 into 
lymphopenic mice, showing a pathogenic role for both subsets in the EAE mouse 
model (O'Connor et al., 2008; Stromnes et al., 2008). Moreover, in a 
spontaneous model of EAE, there is a presence of both Th1 and Th17 cells in 
the CNS suggesting role of both subsets in its pathogenesis (Krishnamoorthy et 
al., 2006; Pollinger et al., 2009). Currently this concept is again modified because 
of the presence of IL-17+/IFNγ+ double positive populations under in vitro culture 
conditions as well as in vivo inflammatory conditions, suggesting an intricate 
relationship between Th17 and Th1 differentiation programs. I have shown that 
T-bet, a transcription factor which is considered to be Th1 specific, is also 
upregulated during Th17 differentiation. The presence of T-bet in Th17/Th1 or 
only Th17 cells has been demonstrated by other investigators also (Yang et al., 
2009). This suggests that there is possible an IL-12 independent, but IL-23 
dependent pathway for an up-regulation of T bet. This is shown to be true as the 
absence of IL-23 signaling in Th17 cells prevented T- bet up-regulation (Hirota et 
al., 2011). In this study I have shown that Notch1 expression is increased when 
naïve CD4+ T cells were stimulated with anti CD3/CD28 signal along with Th17 
skewing cytokines. Furthermore I demonstrated that Notch1 binds to the ROR-γt 
and T-bet promoter under the Th17 differentiating conditions. It seems that IL-23 
(present in Th17 skewing cytokine cocktail) upregulates both ROR-γt and T-bet 
expression in Th17 precursor cells. In this respect, Notch1 (upregulated by the 
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TCR signal) binds and activates both promoters, resulting a Th17/Th1 mosaic 
population. The current literature only supports plasticity of Th17 cells and 
argues against a conversion of Th1 cells to Th17 subtype (Lee et al., 2009). But 
in my experiments, upon in vitro Th1 differentiation, I could observe IFNγ+/IL-17+ 
double positive cells. Further experiments have to be performed to study 
transformation of Th1 to Th17 subset and vice-versa. It may be possible that IL-
12 and IL-23 have convergent signaling pathways due to a shared IL-12 receptor 
β1 subunit, further contributing to the Th1/Th17 mosaic phenotype. 
 Th1/Th17 double producing cells are present in several autoimmune 
diseases in human for example multiple sclerosis (Edwards et al., 2010), 
rheumatoid arthritis(Nistala et al., 2010) and inflammatory bowel disease 
(Kleinschek et al., 2009) . Since Notch signaling regulates the differentiation of 
either subset, Notch inhibitors can be a potential therapeutic intervention for 
these diseases.  
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CHAPTER VI 
DISCUSSION AND FUTURE DIRECTIONS 
 With research related to the Th17 subset of CD4+ T cells gaining 
momentum in the field of immuno-biology and due to its newly discovered role in 
various autoimmune diseases, HIV infections and cancer, the study of the 
regulation of this subset is of utmost importance. Notch signaling plays a role in 
several stages of T cell development. The importance of Notch in T cells can be 
emphasized by the fact that in absence of Notch signaling, lymphoid progenitors 
fail to become T cells in thymus and acquire a B cells phenotype by default 
(Radtke et al., 1999; Tan et al., 2005; Wilson et al., 2001). Moreover, 
overexpression of Notch signaling in immature thymocytes leads to T cell 
leukemia (Lin et al., 2006) (Bellavia et al., 2000; Dumortier et al., 2006). In this 
study, I have demonstrated the role of Notch in dictating peripheral T cells 
differentiation, particularly towards the Th17 lineage. I have observed that in the 
absence of Notch signaling, Th17 associated cytokines are significantly reduced 
even in the presence of a Th17 polarizing environment. This strongly suggests 
that Notch signaling is one of the important Th17 lineage determining factors. 
The effects of Notch inhibition on Th17 differentiation are observed only within 
24-48hrs, but not at later time points (after 5 days) suggesting that Notch signals 
are required for the very initial steps
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of Th17 differentiation. It has been shown before that Notch colocalizes with the 
CD4 coreceptor in TCR activated T cells, suggesting that it acts at the T cell-APC 
interface to regulate T cell differentiation (Benson et al., 2005).  A role for Notch 
as a regulator of T helper cell differentiation is absolutely fascinating, but remains 
very controversial.  Notch is known to direct activated T cells towards both Th1 
(Minter et al., 2005) or Th2 (Amsen et al., 2004) differentiation. This paradoxical 
role of Notch signaling specified by several laboratories may be due to 
differences in experimental models, Notch constructs and even gamma 
secretase inhibitors used. In the current study, I tried to answer this question by 
using in vitro differentiation assays, polarizing naïve CD4+ T cells towards Th1, 
Th2 or Th17 subsets. I observed that not only there is differential upregulation of 
Notch paralogs but also different levels of expression of individual Notch isoforms 
in different Th subsets. It has been shown previously that Notch3 expression 
increases when Th cells commit to the Th1 pathway (Maekawa et al., 2003). 
Consistent with this finding, my results have also shown upregulation of Notch3 
in Th1 differentiated cells.  On the contrary, Notch1 is upregulated in Th17 
differentiated cells. It may be possible that different Notch paralogs have variable 
downstream target genes. Alternatively strength of Notch1 signaling might 
correlate with T helper cell differentiation with maximum Notch1 expression 
favoring Th17 subset differentiation. Another possibility is that a combination of 
different paralogs and their binding to promoters can result in different outcomes. 
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In both ROR-γt and IL-17 promoters, I observed adjacent putative CSL binding 
sites, suggesting cooperative and/or competitive binding of different Notch 
paralogs to these promoters. Binding of Notch as a dimer (Notch1 and 3) is 
already shown to regulate the c-myc and pre-TCR promoters (Liu et al., 2010). 
This is an attractive reasoning, but specific knockdowns of each Notch paralogs 
and ChIP assays have to be performed to reach a definitive conclusion.  
ROR-γt is the most important Th17 lineage determining factor. It is a transcription 
factor which is necessary and sufficient for Th17 differentiation(Manel et al., 
2008). It binds directly to the IL-17 promoter and regulates Th17 differentiation 
(Jetten et al., 2001). Consistent with previous literature, I have also observed 
upregulation of ROR-γt expression in Th17 differentiated cells. I found by 
chromatin immuno-precipitation that Notch1 binds to the ROR-γt promoter in 
Th17 cells. Interestingly Notch1 also binds to the IL-17 promoter in Th17 
differentiated cells, suggesting that Notch1 drives Th17 polarization by binding 
both the proteins. Further, I observed an increase in T-bet transcript levels in the 
Th17 differentiated cells. This is very intriguing, as T-bet is a Th1 specific 
transcription factor (Afkarian et al., 2002). This presence of T-bet transcripts may 
explain the presence of IFNγ/IL-17 double positive cells in Th17 cells. Since T-
bet is a transcription factor downstream of the IL-12R, but my in vitro Th17 
differentiation protocol does not involve IL-12, but rather IL-23, the important 
questions to be asked are what causes IL-12 independent upregulation of T-bet, 
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and is Notch involved in T-bet promoter regulation. It has been shown that IL-
23R can also activate T-bet as it shares IL-12R-β1 subunit with IL-12R (Hirota et 
al., 2011). Surprisingly we observed that Notch1 also binds and regulates the T-
bet promoter in Th17 differentiated cells as shown by ChIP assays and luciferase 
assays. Thus we proposed a putative role for Notch in Th17/Th1 cells co-
differentiation. This observation is validated in vivo in our studies as feeding EAE 
mice with Notch signaling inhibitor GSI abrogated the disease. Further GSI 
treatment downregulates both IFNγ and IL-17 expression in restimulated 
splenocytes. Therefore Notch, being a cytokine modulator, is a promising 
therapeutic target for the treatment of multiple sclerosis.   
 My study emphasizes the importance of Notch as a modulator of immune 
response. It’s ability to bind to the various promoters and recruit histone acetyl 
transferases (p300, PCAF (p300/CBP associated factor) and GCN5 (general 
control of amino acid synthesis 5) (Kurooka and Honjo, 2000; Oswald et al., 
2001; Wallberg et al., 2002) may indicate an indispensable role of Notch in 
opening up chromatin and transcriptional activation. Future studies on the 
transcriptional complexes recruiting Notch to these promoters have to be 
performed to explain the pleiotropic effects observed for Notch. 
 It is clear from several studies that different ligands drive different 
outcomes in peripheral T cells, with DLL ligands preferentially driving Th1 
(Amsen et al., 2004) and Th17 responses (Mukherjee et al., 2009) and Jagged 
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ligands (Amsen et al., 2004) driving Th2 responses. Consistent with a recent 
published report (Mukherjee et al., 2009), my experiments have also shown 
upregulation of DLL-4 ligand in Th17 differentiation. Notch ligands are expressed 
by antigen presenting cells, but surprisingly, my experiments have shown them to 
be present on CD4+ T cells as well. It has been known that inorder to achieve 
signal directionality, a signal receiving cell often downregulates Notch ligand 
expression (Bray, 2006). It is thus possible that when CD4+ T cells are present 
together with antigen presenting cells, CD4+ T cells downregulate their ligands. In 
the absence of antigen presenting cells as represented by my experiments, CD4+ 
T cell apparently combine the signal sending and signal receiving functions. 
Therefore they do not downregulate their ligand expression. Again this 
explanation warrants further evaluation and experiments have to be performed 
including specific knockdowns of individual Notch ligands to study their 
physiological significance. The next question that comes to mind is what 
regulates differential upregulation of Notch receptors and their interaction with 
Notch ligands in different T helper subsets? Fringes are N-acetylglucosaminyl-
transferase that add N-acetylglucosamine (GlcNAc) sugar to the O-fucose group 
of the Notch extracellular domain in the Golgi, followed by addition of  galactose 
and sialic acid(Moloney et al., 2000). It has been shown recently that Fringes 
(Lunatic, Radical and Manic) regulates the level of Notch glycosylation and its 
subsequent interaction with Delta or Jagged(LaVoie and Selkoe, 2003).  In the 
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presence of Fringe, Notch signals strongly when interacted with Delta, but 
reduced signaling is observed following interaction with Jagged (Bruckner et al., 
2000).  My preliminary results using in vitro differentiation (Fig. 39), have 
suggested differential expression of Fringes in Th1, Th2 and Th17 subsets, 
suggesting that different pathogenic stimuli and/or cytokine environments can 
affect expression of Fringes, which can further dictate Notches’ ability to bind and 
signal through different ligands, and thus different T helper cells differentiation. 
 
Significance: Notch inhibitors, potential therapeutic targets for Multiple Sclerosis. 
 Abnormalities in Notch signaling have been associated with different 
diseases, for example cancers (T-cell acute lymphoblastic leukemia) (Sharma et 
al., 2007) and genetic disorders (Alagille syndrome, CADASIL (Cerebral 
Autosomal Dominant Arteriopathy with Sub-cortical Infarcts and 
Leukoencephalopathy)) (Joutel et al., 2000; Oda et al., 1997). More recently, 
Notch overexpression has been observed in patients with rheumatoid arthritis 
(Jiao et al., 2010), autoimmune thrombocytopenia (Ma et al., 2010) and systemic 
lupus erythematosus (Sodsai et al., 2008). A primary role for Notch in multiple 
sclerosis lies in modulating immune responses as Notch affects autoreactive Th1 
cell differentiation (Jurynczyk et al., 2005; Minter et al., 2005). My results have 
shown that Notch plays role in Th17 differentiation as well. Moreover gamma 
secretase inhibitors significantly reduce both Th1 and Th17 associated cytokines 
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in EAE model. A secondary contribution for Notch signaling lies in inhibiting 
oligodendrocyte maturation, preventing myelin repair in multiple sclerosis 
(Genoud et al., 2002; Stidworthy et al., 2004). Thus inhibiting Notch signaling can 
be an effective way of treating MS patients, as it will prevent pathogenic cytokine 
secretion and promote remyelination. 
 Besides the studies presented here, Notch signaling inhibitors have been 
used to treat EAE, mouse model of MS. In our studies, pharmacological γ-
secretase inhibitors (Ly 411,575) downregulated Th1 and Th17 responses and 
ameliorated the disease. Injection of specific Notch3 neutralizing antibody also 
decreased Th1 and Th17 responses in vivo (Jurynczyk et al., 2008b). Moreover, 
DLL1 neutralizing antibody decreases Th1 responses and EAE symptoms, while 
Jagged 1 neutralizing antibody was shown to aggravate disease (Elyaman et al., 
2007).   
Gamma secretase inhibitors are the drugs of choice as they are already in 
clinical trials for treatment of Alzheimer’s disease and T cell leukemia (Fleisher et 
al., 2008; Siemers et al., 2005). However potential side effects of this drug should 
also be taken into consideration, particularly toxicity to GI tract (Wong et al., 
2004).  Long term use can also lead to problems in lymphoid development and to 
myeloproliferative diseases (Qyang et al., 2004; Wong et al., 2004) or skin 
cancers (Nicolas et al., 2003). 
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 Future studies have to be performed aiming to minimize side effects of 
Notch inhibition. For example, specific Notch inhibitors or GSI has to be 
synthetically modified to facilitate their homing to particular organs and restrict 
Notch inhibition to diseased site. In case of Multiple Sclerosis, specific Notch1 
siRNA or GSI has to be targeted to blood-brain barrier endothelial cells (either 
tagging them with homing receptor for specific brain endothelial cells-along with 
transferrin, such drug is taken up by transferrin receptor. Recently role of 
nanotechnology in delivering drug in across blood brain barrier is also been 
investigated (Silva, 2008).   
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Figure 40: Regulation of Th17 differentiation and Th17 mediated 
disease by Notch: Invitro differentiated Th17 cells upregulate Notch1 
expression. Notch1 binds to ROR-γt and IL-17 promoter and regulate Th17 
differentiation. In addition, Th17 cells also has upregulation of expression of 
T-bet transcription factor and presence of IFNγ/IL-17 double positive cells. 
Notch binds to T-bet, but not GATA3 in Th17 cells. Inhibition of Notch 
signaling by gamma secretase inhibitors ameliorates EAE symptoms 
consistent with downregulation of IL-17 and IFNγ.
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CHAPTER VII 
MATERIALS AND METHODS 
Cell lines and constructs:  
HEK293 T cells and Jurkat T cells were obtained from the American Type 
Culture Collections and used for luciferase assays (Manassas, VA). The human 
plasmid NotchIC (1-4) constructs were generated by cloning NotchIC into BamH1 
and EcoRI sites of pcDNA3.0 (Invitrogen). Pheonix-Eco cells of retroviral 
packaging cell lines were transfected for producing retroviral supernatants for 
Notch1 overexpression experiments. Active Notch1IC was expressed from LZRS 
retroviral construct. 
 
Media: 
293T cells and phoenix packaging cells (Phoenix-Ampho) were cultured in 
DMEM (Invitrogen). Jurkat T cell were cultured in RPMI (Mediatech, Inc, 
Manassas, VA) Primary cells were cultured in serum free X-VIVO 20 media 
(BioWhittaker, Walkersville, MD). Transfections were done in serum free Opti-
MEM media (Invitrogen). 
 
Drugs and chemicals: 
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Gamma secretase inhibitors DAPT (GSI IX, Ly 374973, (3,5-
Difluorophenylacetyl)-L-Alanyl-PhenylGlycinebutyl Ester)(Sigma Aldrich, St 
Louis, MO), Compound E(GSI XXI, (S,S)- 2-[2-(3,5-Difluorophenyl)-acetylamino]-
N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-
propionamide)(Alexis Biochemicals, San Diego, CA), Ly 411,575 ((Searfoss et 
al., 2003) and IL-CHO (GSI XII, Z-ILE-LEU-Aldehyde)(Palaga et al., 2003) were 
dissolved in DMSO and used in concentration as indicated in figure legends.  
 
Cell purification:  
Peripheral Blood Mononuclear cells (PBMC) were prepared from buffy 
coats obtained from human healthy donors (Lifesource, Glenview, IL) on Ficoll-
PAQUE gradient (GE healthcare,Uppsala, Sweden). Naïve CD4+ T cells were 
purified from PBMC by depletion of Non T helper cells and memory CD4+ T cells 
using LS columns according to manufacturer’s instructions (Miltenyi Biotech, 
Sunnyvale, CA). Briefly,  human purified CD4+ T cells were incubated with a 
cocktail of biotinylated CD45RO, CD8, CD14, CD15, CD16, CD19,  CD25, CD34, 
CD36, CD56, CD123, anti-TCRγ/δ, anti-HLA-DR, and CD235a (glycophorin A) 
antibodies. These cells were subsequently magnetically labeled with anti-Biotin 
microBeads for depletion and passed through magnetic column. Naïve CD4+ T 
cells (CD4+CD45RA+CD45RO-) were verified to around 93-96% pure before 
proceeding with polarization experiments.  
133 
 
 
 
Cell culture and in vitro polarization:  
Jurkat T cells were cultivated in 370C incubator and 5% CO2 in RPMI 1640 
medium (Mediatech, Inc, Manassas, VA) supplemented with 10% FBS (Cellgro, 
Mediatech, Manassas, VA), 2mM glutamine, 1mM pyruvate, 10mM HEPES and 
0.1 mM nonessential amino acids (all supplements are from Lonza, Walkersville, 
MD). 293 T cells were cultured in DMEM medium ( Mediatech, Manassas, VA) 
supplemented with 10% FBS ( Cellgro, Mediatech, Manassas, VA), 2mM 
glutamine, 1mM pyruvate ( Lonza, Walkersville, MD).  Human naïve CD4+ T cells 
were in vitro  polarized towards Th17 subset in X VIVO-20 serum free medium 
(BioWhittaker, Walkersville, MD) supplemented with 2mM glutamine. For in vitro 
polarization assays naïve CD4+ T cells were plated at the density of 2x106 per ml 
in 24 well plates (1.5ml/well) with beads coated with anti-CD3 and anti-CD28 
(Dynabeads, Invitrogen, Norway) and pulsed with 10U/ml recombinant human IL-
2 on day 0. All antibodies and recombinant cytokines used in Th subset 
polarization were purchased from R&D systems, Minneapolis MN. The following 
antibodies and cytokines were added at the time of plating in 24 well plates  Th1: 
1ng/ml IL-12, 10μg/ml anti- IL-4; Th-2: 10 ng/ml IL-4 and 10 ug/ml IFN-; Th-17: 
10 ng/ml TGF-β1, 10 ng/ml IL-6, 10 ng/ml IL-23, 10 ng/ml IL-1β,  10μg/ml anti-IL-
4 (AB-204-NA) and 10μg/ml anti-IFN-gamma (AB-285-NA).  
 
ELISA:  
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Supernatants were collected and stored at -20 until use. 100 μl 
supernatant fluids were analyzed in triplicate by standard ELISA (ebioscience) for 
detection of human IFN-gamma, TNF-alpha, IL-5, IL-17A, IL-17F, IL-21 and IL-22 
(representative of each T helper subset). Briefly, these ELISA kits make use of 
capture antibodies clone NIB42, MAB TRFK 5, 64cap17, SHLR17, H17F10A7, 
eBio2B2-G20 (2B2-G20), 22URTI respectively and detection antibodies Clone 
4S.B3, JES-5A10, 64Dec 17, eBio3A3-N2 (3A3-N2), IL22JOP respectively. The 
detection antibodies are labeled with biotin and avidin-horse radish peroxidase 
labeled enzyme was used (eBioscience, San Diego, CA). Tetramethylbenzidine 
(TMB) substrate (ebioscience) is used for development of the assay. Color 
development is stopped by addition of stop solution consisting of 0.16M sulphuric 
acid (ebioscience). Standard solutions are plated to represent a range of 0 to 
1000 pg of cytokine to generate a standard curve. Analysis is performed in an 
ELISA reader ( BioWhittaker, ELX 808) at  450 nm. Cytokine concentration was 
analyzed based on standard curve of known concentration of standards. 
 
Dual Luciferase assay: 
293 T cells were plated in 60mm culture dishes and were co-transfected 
with 1μg Notch1ICexpression vector cloned in pcDNA3 along with 1μg human IL-
17 promoter cloned in firefly luciferase pGL3basic (kind gift from Dr Sarah 
Gaffen) and 0.1μg pRLTK plasmid that contains Renilla luciferase gene to 
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normalize transfection. Briefly transfections were performed with 12μl FuGene 6 
(Roche) and 100μlOpti-MEM media, luciferase assays were performed 48 hours 
after transfection according to manufacturer’s instructions. Harvested cells were 
washed with 1xPBS and incubated with 500μl 1xPassive Lysis Buffer for 30 
minutes. After centrifugation at 40C at 14000rpm for 5 minutes, 10μl of the 
supernatant was assayed. Luciferase was measured using Sirius Luminometer 
(Berthhold Detection Systems). Firefly luciferase values were normalized with 
renilla luciferase values. 
 
Surface and intracellular staining:  
For intracellular cytokine staining, cells were incubated for 6hrs with 
phorbol 12-myristate 13-acetate (PMA)(50ng/ml;Sigma, St Louis MO), ionomycin 
(500ng/ml;Sigma, St Louis, MO) and Golgi-Stop ( BD biosciences, San Jose, 
CA). Cell staining was performed by incubation for 30 minutes on ice with 
fluorescently labeled antibodies; Phycoerythrin (PE) labeled anti-human CD4, 
Fluorescein Isothiocyanate (FITC) labeled anti-human CD45RA (Becton 
Dickinson, NJ). The cytofix/cytoperm (BD, Bioscience, CA) was used to fix and 
permealize cells according to manufacturer’s instructions. Briefly cells were fixed 
with 200μl of 2% paraformaldehyde for 15 minutes at room temperature followed 
by washing with 1xPBS. Then fixed cells were permeabilized with buffer 
containing 0.1% saponin, 0.1% Na-azide, 4% Heat inactivated FBS in 7.5 ml 
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1xPBS). For intracellular staining, antibodies used were Allophycocyanin (APC) 
labeled anti-human IFNγ, PE labeled anti-human IL-17A, FITC labeled anti-
human IL-4 (ebioscience, CA). Flowcytometry were performed using 
FACSCalibur and analysed using FLOWJO software. 
 
Production of retroviral particles and retroviral infection: 
Phoenix-Ampho cells (2x105/ml) were plated one day before transfection 
in 100mm culture dishes.  Next day, 4μg of DNA construct (N1IC in LZRS 
retroviral construct or LZRS empty vector) were incubated for 30 minutes with 
12μl of FuGene 6 I OptoMEM to a final volume of 200μl. This mixture was then 
added to Phoenix –Ampho cells. After 72 hrs of transfection, Phoenix-Ampho 
cells were positively selected by adding 1μg/ml puromycin. After selecting them, 
cells were cultured in puromycin free DMEM. Retroviral particle were obtained 
after 48 and 72hrs and were filtered through 0.45μm filter (Nalgene).  For 
retroviral infection, naïve CD4+ T cells were stimulated for 24 hrs with anti-CD3 
and anti-CD28 and then retroviral particles were added to these stimulated cells 
aling with 4μg/ml polybrene (Millipore) and spun for 1hr at 300xg. 
 
Semiquantitative RT-PCR and quantitative Real time PCR: 
RNA isolation 
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Total RNA was extracted using RNeasy mini kit (Qiagen), following 
manufacturer’s instruction. Briefly cells were resuspended in 1 ml of RPE buffer 
(containing guanidium thiocynate) and passed through QIAshredder (Qiagen) to 
homogenize the cells.  Then 70% ethanol is added to the lysate to promote 
binding of RNA to RNeasy columns. RNA bound to RNeasy column would be 
washed by ethanol and eluted with RNAase free water. Extracted RNA was 
quantified by optical density of 260nm. 
 
Semiquantitative RT-PCR 
RNA was treated with DNase(Promega) and  cDNA was synthesized with 
reverse transcription (Superscript III, Invitrogen)  of 1μg of RNA with random 
hexamers (Invitrogen). For semi-quantitative PCR, following primers were used:  
Hey1 forward: TGGATCACCTGAAAATGCTG 
Hey1 reverse: TTGTTGAGATGCGAAACCAG 
Hes5 forward: TCAGCCCCAAAGAGAAAAAC 
Hes5 reverse: TAGTCCTGGTGCAGGCTCTT 
 
Quantitative real time PCR: 
 Real time PCR was performed using the iSYBR Green Supermix (Bio-
Rad, CA) and 7300 real time PCR (Applied biosystem, CA). The expression of 
each gene was normalized to expression of 18S by 2-ddCT method (Livak and 
138 
 
 
 
Schmittgen, 2001). Error bars were calculated based on triplicate measurements 
of each gene. PCR primers used are Notch1 Forward: 5’-GTC AAC GCC GTA 
GAT GAC C- 3’, Reverse: 5’-TTG TTA GCC CCG TTC TTC AG-3’; T-bet 
Forward: 5’-ACA GCT ATG AGG CTG AGT TTC GA-3’, Reverse: 5’-GGC CTC 
GGT AGT AGG ACA TGG T-3’; GATA3 Forward: 5’-GGA CGC GGC GCA GTA 
C-3’, Reverse: 5’-TGC CTT GAC CGT CGA TGT TA-3’; ROR-γt Forward: 5’-TTT 
TCC GAG GAT GAG ATT GC-3’, Reverse: 5’-CTT TCC ACA TGC TGG CTA 
CA-3’; 18SrRNA Forward: 5’-GGC GCC CCC TCG ATG CTC TTA G-3’, 
Reverse:5’- GCT CGG GCC TGC TTT GAA CAC TCT-3’.; Hey1 Forward: 5’- 
TGG ATC ACC TGA AAA AGT TG-3’, Reverse:5’- TTG TTG AGA TGC GAA 
ACC AG-3’ 
 
Immunoblotting analysis: 
Protein lysis and quantification: 
The cell pellet was resuspended in 100μl of RIPA lysis buffer (1%NP-40, 
10mM Tris (pH7.6), 150mM NaCl, 0.1%SDS, 0.5% deoxycholate and 2mM 
EDTA) with protease inhibitor cocktail (Pierce). The cells in RIPA buffer were 
incubated on ice for 15minutes. Finally cells are centrifuged at 14000rpm at 40C 
for 15minutes. The cell lysate obtained was quantified for protein concentration 
by Bradford assay. Bovine serum albumin was used as a standard to measure 
protein concentration. 
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Western blot:  
 For immunoblot analyis, 30-50 μg of protein from whole cell lysate is 
mixed with 6x Laemmli sample buffer (4%SDS, 200mM DTT, 120mM Tris-HCl 
(pH 6.8), 50% glycerol and 0.02% bromophenol blue) and ran on 6-12% Sodium 
Dodecyl Sulfate- Polyacryamide gel electrophoresis (SDS-PAGE) gels. After 
proteins got resolved in gel, they were transferred to polyvinylidene difluoride 
(PVDF) membrane (Millipore). The membrane was blocked with 5%nonfat dry 
milk in PBST followed by probing with primary antibody overnight. Next the 
membrane was washed with TBST (0.05% Tween 20 in 1xPBS) three times and 
incubated with fluorescent secondary antibodies Secondary antibodies (goat anti-
rabbit IgG-Alexa Fluor 680( Invitrogen), donkey anti-rabbit IgG-IRDye 800 
(Rockland) and goat anti-mouse IgG-AlexaFluor-680 (Molecular Probes, and 
donkey anti-mouse IgG IRDye 800(Rockland) for detection using the LI-COR 
infrared scanning system (LI-COR Biosciences). Primary antibodies used were: 
rabbit polyclonal anti human Notch1 (C20) (Santa Cruz, CA), rabbit polyclonal 
anti-activated Notch1 (Rockland, PA), rabbit polyclonal anti-human Notch3 
(M134) ( Santa Cruz, CA) and rabbit polyclonal anti Notch4 (H225) (Santa Cruz, 
CA). β-actin (Sigma Aldrich, MO) was used as a loading control. 
 
RNA- mediated interference:  
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 To knock down of Notch1, naïve CD4+ T cells were purified and were 
nucleoporated with siRNA specific for human Notch1 or scrambled siRNA(Santa 
Cruz Biotechnology, Santa Cruz, CA) using Amaxa Nucleoporator system 
according to manufacturer’s instructions. Briefly, 5-10 x106 CD4+ cells were 
resuspended with 100 μl of nucleofector solution and transfected with 100nM 
siRNA using nucleofector program U-014  (Amaxa, Lonza, Switzerland). After 
transfection cells, were incubated for 6h at 370C, and then were stimulated with 
anti- CD3/CD28 coated magnetic beads and were cultured in Th-17 polarizing 
conditions for additional 48hrs.  
 
MTS assay: 
 To assess cell viability MTS assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt;MTS) and electron 
coupling reagent, phenazine methosulfate (PMS) were used. 1x105 cells/ml 
treated with GSI or DMSO was plated in 96 well plates in triplicates. 20μl of Cell 
Titer 96Aqueous one solution reagent was added in each well of 96 well plates 
containing 100μl of culture media. Plate was incubated for 4 hrs at 370C in 
humidified 5% CO2. Absorbance was measured at 490nm using 96 well plate 
reader POLARstar Omega (BMG Labtech, Germany). 
 
Chromatin immunoprecipitation assay (ChIP):  
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ChIP assay was performed using 1X107 naïve CD4+ T cells stimulated 
with anti CD3/CD28 coated magnetic beads (concentration of 1bead/cell) 
differentiated to Th0 ( no cytokines)  and Th17 ( presence of Th17 skewing 
cytokines cocktail as described in Invitro polarization section) pretreated with 
DMSO and GSI (10μM) for 24 hrs at 370C and 5%CO2  and analyzed using ChIP 
assay kit ( Upstate Cell Signaling Solutions). Briefly cells were fixed in 1% 
formaldehyde for 10minutes, and then 250μM glycine was added to quench 
unreacted formaldehyde for 5minutes. Five hundred microliters of cell lysis buffer 
was added following by 500μl of nuclear lysis buffer. Chromatin-DNA were 
sonicated using ultrasonic processor (GEX -130 PB, 50% of maximum power) 
with 5 sec pulse and 1 min standing on ice. Lysate was diluted in ChIP dilution 
buffer and 5% lysate was saved as input DNA. For immunoprecipitations 5μg of 
anti-humanNotch1 or anti human IgG was added in 500μl of cell lysate for 2hrs at 
4OC followed by 60μl of protein A/G agarose suspension (Calbiochem, CA) and 
again incubated at 4OC overnight with rotation.  DNA–protein complex were 
eluted in  elution buffer, and crosslinks were reversed with at 650C overnight in 
the presence of 5M NaCl. Released proteins were digested with 10mg/ml 
proteinase K for 1hr at 45OC, and DNA was recovered using DNA purification 
columns (Qiagen, Valencia, CA).The following primers were used for quantitative 
as well as standard PCR. IL-17 primer sets are 17 CSL1 (expected size 170bp) 
(forward) 5’-TTGACCCATAGCATAGCAGC-3’, (reverse) 5’- 
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TTCAGGGGTGACACCATTTT-3’; 17CSL2 (expected size 199bp) (forward) 5’- 
GAAAATCTCGTGTCTCTTGAACC-3’, (reverse) 5’ 
TTCCTCACAGATTCCTTGGC-3’; 17CSL3 (expected size 147bp) (forward)- 5’ 
TTCCACTTTCCACTTCCCAC-3’ (reverse) 5’- TTCCTCCCTGTCCTGCTCTA-3’; 
17CSL4 (expected size 136bp) ( forward) 5’- CAATTGGGAAAAGCAAGCAT-3’, 
(reverse) 5’- CCCTACTGCCCCTCCTCTAC-3’. RORC primer sets are RCBF1 
(expected size 129bp) (forward) 5’- ATCTCCAGCCTCAGCTTTGA-3’ (reverse) 5’ 
GATGCCCCTGTTTTCTTGAG-3’; RCBF2 (expected size 223bp) (forward) 5’- 
AGAGGGACTCCTTGCCTCTC-3’. Antibodies used were rabbit anti human-
Notch1, normal rabbit IgG (both were Santa Cruz biotechnology). Conditions for 
real time PCR are 50OC 2 min.,95OC 10 min, 95OC 15 sec, 60OC 1min (40 
cycles). Conditions for PCR are 950C 5 min, 950C 30s, 550C 1min, 720C 30s (35 
cycles), 720C 2min. 
 
In vivo GSI treatment: 
For in-vitro polarization assays C57BL/6 mice were purchased from 
Jackson laboratory. For the EAE experiments, 8-12 weeks old female SJL mice 
were purchased from Charles River Laboratory (Wilmington, MA).  All mice were 
housed in the animal care facility at the University of Massachusetts, Amherst in 
accordance with the Institutional Animal Care and Use Committee (IACUC) 
guidelines. The GSI administered in vivo was LY-411,575 (LY) formulated for two 
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doses 5mg/kg and 2.5 mg/ kg. Mice were fed 5mg/kg LY chow for four weeks. 
They were immunized at this point, and then fed 2.5mg/kg LY chow for two 
weeks before being returned to the 5mg/kg LY chow until the end of the 
experiment.  
 
EAE Evaluation: 
EAE was induced by immunizing mice in the flank with 50μg PLP 
(139-151)
 
(Invitrogen, Carlsbad, CA) supplemented with 400μg Mycobacterium tuberculosis 
H37RA (Difco, Detroit, MI). Pertussis toxin (Ptx; Sigma 200ng) was injected 
interaperitonially on the day of immunization. The progression and severity of 
disease was monitored and scored from 0-5 as follows: Score 0-no disease; 1-
limp tail, 2-hind limb weakness; 3-hind limb paralysis; 4-hind and fore limb 
paralysis; 5-morbidity and death. Data is reported as the mean daily clinical score 
(Hofstetter et al., 2007; Jurynczyk et al., 2008a; Serada et al., 2008). 
Mice were anesthetized and perfused through the left cardiac ventricle 
with PBS during the peak of disease (day 15 post immunization). Spinal cords 
and spleens were removed by dissection.  Splenocytes were cultured at 37°C 
with medium alone or with different concentrations of PLP (139-151) antigen for 5 
days. To prepare a single cell suspension, spinal cords were cut into pieces and 
the tissues were mashed and passed through a 70 μm mesh. Mononuclear cells 
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were isolated over a Percoll gradient and were then cultured with PLP (139-151) 
antigen for 5 days. Cells from the spinal cord were stained for CD4+ and CD8+ T 
cells. IL-17 ELISAs were then performed on supernatants from all re-stimulated 
cells.
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